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ABSTRACT
Evidence supporting the role of hematopoietic stem cell transplantation (SCT) in the therapy of acute lympho-
blastic leukemia (ALL) in children is presented and critically evaluated in this systematic evidence-based review.
Specific criteria were used for searching the published literature and for grading the quality and strength of the
evidence and the strength of the treatment recommendations. Treatment recommendations based on the evidence
are presented in a table in this review (Summary of Treatment Recommendations Made by the Expert Panel for
Pediatric Acute Lymphoblastic Leukemia) and were reached unanimously by a panel of ALL experts. The priority
areas of needed future research in pediatric ALL are unrelated marrow or blood donor versus unrelated cord blood
donor allogeneic SCT; alternative, nonfamily allogeneic donor versus autologous SCT; better methods for iden-
tifying high-relapse-risk patients; assessments of the effect of current chemotherapy regimens on early relapse; and
use of pre-SCT detection of minimal residual disease to predict post-SCT outcomes.
© 2005 American Society for Blood and Marrow Transplantation
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1NTRODUCTION
The American Society for Blood and Marrow
ransplantation in 1999 began an initiative to sponsor
vidence-based reviews of the scientiﬁc and medical lit-
rature for the use of blood and marrow transplantation
n the therapy of selected diseases. The steering com-
ittee that was convened to oversee the projects invited
n independent panel of disease-speciﬁc experts to con-
ll terms abbreviated in this article are deﬁned in a Glossary of Terms,
ppendix A, at the end of the article.
B &MTuct each review. Two reviews have been published in
iology of Blood and Marrow Transplantation: one on dif-
use large cell B-cell non-Hodgkin lymphoma in 2001
1] and one on multiple myeloma in 2003 [2].
The following is the third review to result from
his initiative. Its goals are to
. Assemble and critically evaluate all of the evidence
regarding the role of hematopoietic stem cell trans-
plantation (SCT; in this review, SCT refers to the
general term hematopoietic stem cell transplantation, in-
cluding bonemarrow transplantation [BMT], periph-
eral blood SCT [PBSCT], or both) in the therapy of
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8pediatric (21 years) acute lymphoblastic leukemia
(ALL).
. Make treatment recommendations based on the
available evidence.
. Identify needed areas of research.
The published literature was graded on the quality
f design and the strength of the evidence (Table 1) in
systematic manner. Treatment recommendations
ere subsequently graded on the basis of the quality
nd strength of the evidence (Table 2). The treatment
ecommendations of the expert panel are detailed in
able 3.
ITERATURE SEARCH METHODOLOGY
PubMed and MEDLINE, the Web sites devel-
ped by the National Center of Biotechnology Infor-
ation at the National Library of Medicine of the
ational Institutes of Health, were searched by using
he search terms “acute lymphoblastic leukemia” and
transplant” limited to human trials and English lan-
uage. The MEDLINE Subject Heading terms for
ny article about ALL included “acute lymphoblastic
eukemia,” “acute lymphoid leukemia,” and “acute
ymphocytic leukemia,” regardless of which term was
sed in the published article. Therefore, the search by
acute lymphoblastic leukemia” generated all articles
able 1. Grading the Quality of Design and Strength of Evidence*
Levels of
Evidence
1 High quality meta analyses, systematic reviews
of randomized controlled trials (RCTs), or
RCTs with a very low risk of bias
1 Well conducted meta analyses, systematic
reviews of RCTs, or RCTs with a low risk of
bias
1 Meta analyses, systematic reviews of RCTs, or
RCTs with a high risk of bias
2 High quality systematic reviews of case-control
or cohort studies
High quality case-control or cohort studies
with a very low risk of confounding, bias, or
chance and a high probability that the
relationship is causal
2 Well conducted case control or cohort studies
with a low risk of confounding, bias, or
chance and a moderate probability that the
relationship is causal
2 Case control or cohort studies with a high risk
of confounding, bias, or chance and a
significant risk that the relationship is not
causal
3 Non-analytic studies, e.g. case reports, case
series
4 Expert opinion
Reprinted with permission from Harbour R, Miller J. A new
system for grading recommendations in evidence-based guide-
lines. Br Med J. 2001;323:334-336.n ALL even if the article did not use this term to
24eﬁne ALL. The original search included publications
rom January 1, 1980, to August 18, 2002, was updated
n February 18, 2003, and underwent a ﬁnal update
n January 3, 2005. In addition, articles were excluded
f they were not peer-reviewed reports; were editori-
ls, letters to the editor, case reports (10 patients),
hase I (dose-escalation or dose-ﬁnding) studies, re-
iews, consensus conference reports, practice guide-
ines, or laboratory studies with no clinical correlates;
r did not focus on an aspect of therapy with SCT for
he treatment of ALL. The review of SCT for ALL is
ublished as 2 articles: one including studies of pedi-
tric ALL and the other including studies of adult
LL. Articles were excluded from the pediatric ALL
eview if 50% of the study population was 16
ears; these articles are included in the adult ALL
eview [3]. Abstracts and presentations at national or
nternational meetings were also not included as evi-
ence in this review because of their lack of formal
eer review, the limited availability of details on study
esign and results, and because they are usually pre-
ented as preliminary—not ﬁnal—analyses of clinical
rial data.
able 2. Grading the Strength of the Treatment Recommendation*
Grades of
Recommendation
A At least one meta analysis, systematic
review, or randomized controlled
trial (RCT) rated as 1, and
directly applicable to the target
population; or
A systematic review of RCTs or a
body of evidence consisting
principally of studies rated as 1,
directly applicable to the target
population, and demonstrating
overall consistency of results
B A body of evidence including studies
rated as 2, directly applicable to
the target population, and
demonstrating overall consistency
of results; or
Extrapolated evidence from studies
rated as 1 or 1
C A body of evidence including studies
rated as 2, directly applicable to
the target population and
demonstrating overall consistency
of results; or
Extrapolated evidence from studies
rated as 2
D Evidence level 3 or 4; or
Extrapolated evidence from studies
rated as 2
Reprinted with permission from Harbour R, Miller J. A new
system for grading recommendations in evidence-based guide-
lines. Br Med J. 2001;323:334-336.
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Cytotoxic Therapy with Hematopoietic SCT for ALL
BUALITATIVE AND QUANTITATIVE GRADING OF THE
VIDENCE
The hierarchy of evidence, including a grading
cheme for the quality and strength of the evidence
nd the strength of each treatment recommendation,
able 3. Summary of Treatment Recommendations Made by the Exper
Indication for SCT
Treatment
Recommendation*
Highest L
of Eviden
CT vs. chemotherapy
in first complete
remission
B 2
CT vs. chemotherapy
in second complete
remission
B 2
utologous purged
SCT
C 2
utologous, unpurged
SCT
N/A N/A
elated allogeneic
SCT
C 2
nrelated allogeneic
SCT
C 2
elated vs. unrelated
allogeneic SCT
None 2
omparison of
conditioning
regimens
B 1
utologous vs.
allogeneic SCT
None 2
Deﬁnitions: See Table 2.
Deﬁnitions: See Table 1.
The references listed represent the highest level of evidence used to
described in the review.as been established and published as an editorial s
B&MTolicy statement in Biology of Blood and Marrow Trans-
lantation [4]. Tables 1 and 2 are reprinted from the
olicy statement and deﬁne criteria used to grade the
tudies included in the review and grade the treatment
ecommendations. Study design, including sample
for Pediatric Acute Lymphoblastic Leukemia
References‡ Comments
5-8 Demonstrated benefit only for matched
related allogeneic SCT in very-high-
risk (Ph only) ALL. Not
recommended for standard or other
high-risk (ie, induction failure,
hypodiploidy, etc.) patients except in
the context of clinical trial
11-14 Recommended only for matched
related allogeneic transplantation vs.
chemotherapy; however, the
recommendation is tempered
because of one prospective trial that
did not demonstrate a benefit for
transplantation when analyzed by the
presence vs. absence of a related
donor in an intent-to-treat analysis.
Evidence is insufficient to support a
recommendation for an unrelated
allogeneic transplantation vs.
chemotherapy
26-29 Although a majority of patients with
late relapses achieve extended
leukemia-free survival (LFS) with an
autologous purged SCT, the evidence
is insufficient to determine that this
is better than chemotherapy alone.
For those with an early relapse, the
outcomes with autologous purged
SCT are even less promising.
N/A Data are unavailable on outcomes of
unpurged autologous SCT.
41-48 A substantial proportion of patients
achieve extended LFS.
58-59 A substantial proportion of patients
achieve extended LFS.
65-67 Outcomes of related vs. unrelated
donor allogeneic SCT have not been
adequately studied, especially in
patients who have had high-
resolution typing. No
recommendation can be made at this
time.
69-71 TBI-containing regimens have better
outcomes than non-TBI containing
regimens.
74-76 The outcomes of autologous vs.
allogeneic SCT have not been
adequately studied. No
recommendation can be made at this
time.
the treatment recommendation and are not inclusive of all evidencet Panel
evel
ce†
makeize, patient selection criteria, duration of follow-up,
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Table 4. Comparison of Patient Characteristics and Outcomes from Articles Included in the Transplantation versus Chemotherapy Section
Reference
Quality and
Strength of
Evidencea
Patient
Populations
No. of Patients
by Treatment
Regimen
Upper Limit
(Median) of
Age at
Diagnosis (y)
Treatment-
Related
Mortality
Median
Follow-up (mo) LFS/EFS/DFS
Significance:
LFS/EFSb OS
Significance:
OSb
First complete
remission
5 2 MRC UKALL X
and XI trials
Total 452 10-y EFSd Not significant 10-yd Not significant
Allo BMT 101c 15 (not stated) 17.8% 60 BMT 50.4% 61.2%
Chemo 351 15 (not stated) 3.1% 96 overall 39.7% 54.0%
7 2 Multicenter Ph
ALL high-risk
protocols per
center
Total 267 5-y EFS 5-y
Auto 25 12%
Matched Rel 38 20 (8.1)e 8% 87.6e 65% P < .001 72% P  .002
Mismatched
Rel 16
44%
Matched
UnRel 21
43%
Allo
undefined 20
25%
Chemo 147 5% 25% 42%
8 2 AIEOP BMT
trials; Chemo
Trials 8503,
8703, 8803,
9103
Total 160
Rel allo 30
Chemo 130
15 (8.3)
15 (5.7)
10%
4%
48 overall
4-y DFSf
58.5%
47.7%
Not significant Not statedt-it Not compared
9 2 Nordic ALL
population-
based case-
control study
Total 471 Not stated
(minimum
24)
10-y DFS P  .02 for
Allo vs.
matched
Chemo
Not stated Not compared
Rel Allo
BMT 22
15 (not stated) 13% 73%
Matched
Chemo 44g
15 (not stated) 9% 50%
Unmatched
Chemo 405g
15 (not stated) 1% 59%
10 2 Single Canadian
center Ph
ALL
Total 21 At 5 y 4-y EFS Not stated Not stated Not stated
Matched Unrel
or Rel 11
16 (7) 27% 41 53%
Chemo 10 13 (9) 20% 26 33%
Second complete
remission
11 2 IBMTR vs. POG
8303, 8304,
8710, 8862
Total 510 At 5 y Not stated 5-y LFS P < .001 Not stated Not compared
Rel Allo
BMT 255
18 (7) 27% 40%
Chemo 255 18 (6) 14% 17%
T
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Table 4. Continued
Reference
Quality and
Strength of
Evidencea
Patient
Populations
No. of Patients
by Treatment
Regimen
Upper Limit
(Median) of
Age at
Diagnosis (y)
Treatment-
Related
Mortality
Median
Follow-up (mo) LFS/EFS/DFS
Significance:
LFS/EFSb OS
Significance:
OSb
12 2 MRC UKALL X
trial: relapsed,
re-treated pts
Total 432 Not stated
(minimum
24)
4-y EFS P  .05 for
Allo vs.
Chemo
Not stated Not significant
Allo BMT 110h 14 (not stated) 17% 42.6%
Auto BMT 61 14 (not stated) 5% 35.4%
Chemo 261 14 (not stated) 5% 28.2%
13 2 GITMO and
AIEOP trials
Total 287 5-y DFS P  .006i Not stated Not compared
Rel allo
BMT 57
18 (not stated) 19.3% 74 41.1%
Chemo 230 Not stated 2.6% 21.7%
14 2 MRC UKALL R1
trial
Total 206 8-y EFS Not significant Not stated Not compared
Rel donor 67 15 (not stated) Not stated 72 45%
No Rel
donor 139
15 (not stated) 37%
15 2 Population based
Nordic ALL
database
Total 225 Not stated
(minimum
24)
EFS P  .02 Not stated Not compared
Rel Allo
BMT 75
15 (not stated) 19% 40%
Chemo 150 15 (not stated) Not stated 23%
16 2 ALL-REZ BFM
trialsj
Total 165 5-y EFS P < .05 Not stated Not compared
BMT 31k 16 (7.8) 13% 23 36%
Chemo 134 14 (4.4) 4% 56 50%
17 2 ALL-REZ BFM
trials,j matched
case-control
study
Total 162 5-y EFS P < .001 Not stated Not compared
Matched Unrel
BMT 81
18 (not stated) 30% 49 42%
Chemo 81 18 (not stated) 4% 95 17%
18 2 BMT pts from
Leiden
University;
Chemo pts
from DCLSG
Total 122 5-y LFS Not significant Not stated Not significant
Rel Allo
BMT 25
Not stated 20% Not stated 44%
Chemo 97 Not stated 0% 24%
19 2 BFM Chemo/ auto
BMT trials,j
matched case-
control study
Total 104 9-y EFS Not significant Not stated Not compared
Auto BMT 52 15 (4.3) 4% 46 26%
Chemo 52 14 (4.7) 2% 55 32%
20 2 AIEOP centers Total 69l Not stated
(minimum
48)
5-y DFS P  .026 Not stated Not compared
Auto BMT 19 Not stated 16% 56.3%
Rel Allo
BMT 9
Not stated 33% Not stated
Chemo 41 Not stated 12% 12.6%
21 2 Single US center Total 66 5-y DFS P  .03 Not stated Not compared
Rel Allo
BMT 37
17.6 (8.1) Not stated 149 62%
Chemo 29 17 (5.3) 65 26%
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Table 4. Continued
Reference
Quality and
Strength of
Evidencea
Patient
Populations
No. of Patients
by Treatment
Regimen
Upper Limit
(Median) of
Age at
Diagnosis (y)
Treatment-
Related
Mortality
Median
Follow-up (mo) LFS/EFS/DFS
Significance:
LFS/EFSb OS
Significance:
OSb
22 2 CCG-1884 Total 62 2-y EFS P  .017 Not stated Not compared
BMT 19m 21 (not stated) 21% Not stated 37%
Chemo 43 21 (not stated) 0% 18%
23 2 Multicenter
Spanish study
Total 61 Overall DFS P < .025 BMT 34 Not compared
Rel Allo
BMT 21
17 (not stated) Not stated 49 47%
Chemo 40 17 (not stated) 30 9%
24 2 Single US center Total 45 Overall DFS P  .002 Not stated
Rel Allo
BMT 24
16 (8) 8% 33 38% 46%
Chemo 21 15 (7) 0% 20 5% 10%
25 2 2 Italian centers Total 36 Overall DFS P  .01 At 53 mo 48% P  .04
Rel Allo
BMT 17
12 (6) 12% 33 58% At 37 mo 22%
Chemo 19 11 (6) 0% 31 18%
LFS indicates leukemia-free survival; EFS, event-free survival; DFS, disease-free survival; OS, overall survival; MRC, Medical Research Council; UKALL, United Kingdom Acute Lymphoblastic
Leukemia; Allo, allogeneic; BMT, bone marrow transplantation; Chemo, standard chemotherapy comparison group; ALL, acute lymphoblastic leukemia; Auto, autologous; Rel, related donor; Unrel,
unrelated donor; AIEOP, Associazione Italiana di Ematologia ed Oncologia Pediatrica; IBMTR, International Bone Marrow Transplant Registry; POG, Pediatric Oncology Group; GITMO,
Gruppo Italiano Trapianto di Midollo Osseo; ALL-REZ, Relapsed Acute Lymphoblastic Leukemia; BFM, Berlin-Frankfurt-Munster Study Group; DCLSG, Denmark Childhood Leukemia Study
Group; CCG, Children’s Cancer Group; pts, patients.
aQuality and strength of evidence deﬁnitions are listed in Table 1.
bNot signiﬁcant: P  .05.
cThe Allo BMT group includes 76 related Allo BMTs and 25 unrelated BMTs; the chemotherapy group includes 6 Auto BMTs.
dBased on the donor versus no-donor group comparisons, adjusted for time-to-transplantation bias and the prognostic factors, WBC at diagnosis, Ph chromosome status, and ploidy.
eOf 326 patients enrolled in the multicenter trial.
fThe rates for DFS are for the unadjusted comparison. The model adjusting for prognostic factors did not specify estimates of DFS for the BMT versus chemotherapy groups.
gThis study compared the BMT group with the chemotherapy group chosen as controls (matched Chemo group) and with the remaining chemotherapy-treated patients who were not chosen as matched
controls (unmatched Chemo group).
hThe Allo BMT group includes 83 related and 27 unrelated donors.
iThe P value is based on the comparison of Allo BMT versus Chemo from the multivariate model for DFS.
jThere is some overlap among references 16, 17, and 19.
kThe BMT group includes 17 related Allo and 14 Auto BMT patients.
lThis study included only patients with an isolated CNS relapse.
mThe BMT group includes 11 related Allo, 7 Auto, and 1 unrelated Allo BMT patients.
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Cytotoxic Therapy with Hematopoietic SCT for ALL
Bnd treatment plan, also was considered in evaluating
he studies. All data in the text and tables were ﬁrst
bstracted by one author (T.H.) from the original
rticles; they were then double-checked for accuracy
nd clarity by another author (P.L.M.) and at least 2
dditional reviewers (see “Acknowledgments”). In
ome articles, there were discrepancies within the data
eported; ie, the median follow-up reported in the
bstract was not the same as that in the results section,
r data presented in a table did not agree with those
n the text. In these cases, the data most consistent
ith the text of the article were presented in this
eview. The ﬁrst author (T.H.) takes responsibility
f errors remain. Clinical studies were summarized
ith enough detail to give a concise summary of study
esign, sample size, eligibility criteria, treatment
chedule, duration of follow-up, and outcomes mea-
ured. Subjective statements regarding issues such as
hort versus adequate versus long follow-up, small
ersus large sample size, and improper or inappropri-
te study design were not used so that the reader is not
iased by the authors’ opinions.
REATMENT RECOMMENDATIONS
The strength of this review is the detail conveyed
n the text and the study comparisons in the summary
ables at the end of each major section. Table 3 con-
ains the summary of treatment recommendations
ade by the ALL expert panel. Subsequent sections of
he review present the detailed descriptions of the
trengths and weaknesses of the evidence and are spe-
iﬁc to each treatment recommendation. Additional
ections describe other limitations of this review, ad-
itional ongoing studies, areas of needed research, and
igure 1. Descriptive EFS of HLA-typed patients with a sibling
onor versus those with no donor. , sibling donor; ●, no sibling
onor. The EFS is adjusted for time to transplantation, WBC
ount, Ph chromosome status, and ploidy. Vertical lines indicate
ne SE above or below each plotted point. Reprinted with permis-
ion.5uture initiatives. p
B&MTRANSPLANTATION VERSUS CHEMOTHERAPY IN
EDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
Table 4 summarizes the grading criteria, study pop-
lations, patient characteristics, and outcomes from pe-
iatric studies included in the transplantation-versus-
hemotherapy section. Evidence in this section is taken
rom self-described studies of pediatric populations,
ll of which included patients 21 years of age. Evi-
ence is presented with the highest-quality studies
rst; studies of equal quality are presented in descend-
ng order with the largest sample size ﬁrst.
irst Complete Remission
Wheeler et al. [5-6] presented the results of a
ubgroup of very-high-risk pediatric (16 years at the
ime of treatment) patients with ALL from the Med-
cal Research Council (MRC) United Kingdom Acute
ymphoblastic Leukemia (UKALL) X and XI trials (n
473 very-high-risk patients of 3676 total trial pa-
ients) treated from 1985 to 1997. Very-high-risk
LL was deﬁned by a hazard score incorporating age,
ex, and white blood cell count (WBC) at diagnosis or
s Philadelphia chromosome–positive (Ph) ALL,
ear-haploid ALL, or 4 weeks needed to achieve
rst complete remission (CR1). The 473 patients were
dentiﬁed as very high risk and eligible for BMT;
owever, only 452 achieved the stable CR1 required
o proceed to BMT. Ninety-two children had no
iblings, whereas 62 were not typed by choice and
2 had no information regarding typing. The re-
aining 286 (60%) children underwent human leu-
igure 2. Estimates of disease-free and overall survival (SE) in
67 patients treated with transplantation of bone marrow from
LA-matched related donors or chemotherapy only. The curves
ave been adjusted for waiting time to transplantation, so that the 0
n the time axis corresponds to the median time from diagnosis to
ransplantation (6 months). Patients were assigned to this treatment
roup in a time-dependent fashion. Five-year estimates are shown.
values are from the Mantel-Byar test. P .002 for the comparison
f the 2 treatments with respect to overall survival; P  .001 for the
omparison with respect to disease-free survival. Reprinted with
ermission.7
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8ocyte antigen (HLA) typing, of whom 99 (35%)
ad an HLA-matched sibling donor and 76 (27%)
eceived a related allogeneic BMT. Additionally, 25
atients received a matched unrelated donor (URD)
MT and were analyzed with the related allogeneic
MT group; 6 patients received an autologous BMT
nd were analyzed with the chemotherapy group. Re-
ated donor transplantations were performed at 22
enters; autologous BMT, at 18 centers; and URD
ransplantations, at 3 centers.
At a median follow-up of 8 years, the unadjusted
0-year event-free survival (EFS) was 46.8% for the
MT group and 38.3% for the chemotherapy group—a
ifference of 8.5% (95% conﬁdence interval [CI],
3.5% to 20.5%). After adjustment for time-to-trans-
lantation bias and prognostic factors (WBC at diag-
osis, Ph chromosome status, and ploidy), the 10-year
FS was 45.3% for the BMT group and 39.3% for the
hemotherapy group—a difference of 6% (95% CI,
10.5% to 22.5%). Patients were also compared on
he basis of a “biologic randomization”: among the
86 patients who were typed, those with matched
ibling donors were compared with those without
atched sibling donors. The adjusted model yielded a
0-year EFS of 50.4% for the no-donor group and
9.7% for the donor group—a difference of 10.7%
95% CI, 2.6% to 24%; Figure 1). None of these
omparisons reached statistical signiﬁcance.
Arico et al. [7] analyzed the results of a retrospec-
ive multicenter cohort study of 326 pediatric (20
ears at diagnosis) patients with Ph ALL who were
reated between 1986 and 1996 by 10 cooperative
roups or large single institutions in Europe and the
nited States. All were categorized as high-risk ALL
igure 3. Kaplan-Meier estimates of the DFS curves in the groups
f children who underwent allogeneic bone marrow transplantation
BMT) and of matched controls who underwent chemotherapy
CHEMO). Reprinted with permission.8atients because of the presence of the Ph chromo- .
30ome by cytogenetic or molecular criteria. Of the 326
atients, 82% (n 267) achieved a CR with induction
hemotherapy; the remaining patients died of treat-
ent-related mortality (TRM; n  3) or resistant
eukemia (n  56). Children in the CR group (n 
67) were stratiﬁed into 3 prognostic cohorts: worst
WBC 100 000/L; n  80), intermediate (n  92),
nd best (WBC 50 000/L and age 10 years; n 
5). One hundred patients underwent autologous (n
5), matched related donor (n  38), mismatched
elated donor (n  16), or matched URD (n  21)
MT. The median time from diagnosis to BMT for
ll transplant patients was 6.6 months. BMT condi-
ioning and graft-versus-host disease (GVHD) pro-
hylaxis regimens were not stated. The overall TRM
or the BMT group was 27%. Examination of the 3
rognostic cohorts in all CR1 patients (BMT  che-
otherapy group) produced signiﬁcantly different
ates of disease-free survival (DFS) at 5 years: 20%,
0% and 49%, respectively (P .001). HLA-matched
elated donor BMT demonstrated signiﬁcantly better
esults than chemotherapy alone in all 3 prognostic
ohorts (DFS, P  .001; overall survival [OS], P 
002; Figure 2). Multivariate analysis adjusting for
BC, age, sex, and time to transplantation found no
igniﬁcant difference among the chemotherapy, autol-
gous BMT, matched URD BMT, or mismatched
elated donor BMT groups; however, patients in the
atched related donor BMT group had signiﬁcantly
mproved DFS (relative risk [RR]  -0.3; P  .001)
nd OS (RR  -0.4; P  .002) compared with the
hemotherapy group.
Uderzo et al. [8] reported the results of a matched
ase-control study of high-risk pediatric (16 years at
he time of treatment) patients with ALL treated in
R1 on Associazione Italiana di Ematologia ed On-
ologia Pediatrica (AIEOP) trials at 13 Italian centers
rom 1986 to 1994 comparing related HLA-matched
llogeneic BMT with chemotherapy. High-risk pa-
ients were deﬁned as having (1) any cytogenetic ab-
ormalities [t(9;22), t(4;11), or other], (2) Berlin-
rankfurt-Munster (BFM) risk index 1.7, (3) T-cell
mmunophenotype and WBC 100 000/L or day 7
teroid resistance, or (4) failure to achieve CR by day
2 of induction therapy. Thirty BMT patients were
atched to 130 controls (median 4 controls per case
elected from 397 chemotherapy-treated patients) on
nduction protocol, age at diagnosis, WBC at diagno-
is, immunophenotype, and duration of CR1.
At a median follow-up of 4 years, the 4-year un-
djusted DFS was not signiﬁcantly different: 58.5% in
he BMT group and 47.7% in the chemotherapy
roup (Figure 3). The multivariate analysis adjusting
or the 5 matching criteria and time-to-transplanta-
ion bias yielded a hazard ratio for DFS at 2 years after
chievement of CR1 of 0.35 (95% CI, 0.06-1.91; P 
05), which is a nonsigniﬁcant advantage for BMT
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Bersus chemotherapy. Stratiﬁcation by sex (not a
atching criterion) did not affect these results.
Saarinen et al. [9] performed a matched case-con-
rol study of very-high-risk pediatric (16 years at
iagnosis) patients with ALL selected from a popula-
ion-based registry of all children with ALL diagnosed
etween 1981 and 1991 from 5 Nordic countries.
igh risk was deﬁned as having a WBC 50 000/L,
entral nervous system (CNS) involvement at diagno-
is, T-cell immunophenotype, mediastinal mass, or cy-
ogenetic abnormalities. Twenty-two patients received
n HLA-compatible related donor allogeneic BMT in
R1 and were compared with 2 matched controls per
ase treated on standard chemotherapy protocols (n
4; matched control group) as well as with the remain-
ng children in the registry cohort (n  405; un-
atched control group). Donors included HLA-
igure 4. Actuarial probability of leukemia-free survival in matched
ohorts of children receiving chemotherapy or undergoing trans-
lantation, according to the duration of the ﬁrst remission. Re-
rinted with permission.11atched siblings (n  17), HLA-mismatched siblings b
B&MTn  3), and HLA-mismatched parents (n  2).
atched controls had to achieve and maintain a CR
or a period equal to or longer than the case patient’s
ime between CR1 and BMT to control for time-to-
ransplantation bias. Controls were matched for WBC at
iagnosis, age at diagnosis, sex, time period of diagno-
is (July 1981 to June 1984 versus July 1984 to June
986 versus July 1986 to December 1991), and immu-
ophenotype. Matched control patients could not be
elected from the same center or the same country for
ach case.
The 10-year DFS was signiﬁcantly higher in the
MT group compared with the matched control
roup (73% versus 50%; P  .02); there was a higher,
ut nonsigniﬁcant, DFS in the BMT group than in
he unmatched control group (73% versus 59%; P 
12). The median follow-up time was not stated in the
rticle, but the range was 2 to 12.5 years. Signiﬁcantly
ore matched controls relapsed compared with the
MT group (41% versus 9%; P .01). Death in remis-
ion was highest in the BMT group (13% BMT versus
% matched and 1% unmatched control groups).
Sharathkumar et al. [10] performed a retrospective
ohort study of 21 pediatric (17 years) patients with
h ALL diagnosed at or referred to a single Cana-
ian center between 1985 and 2001. All patients re-
eived BFM-based induction therapy protocols; those
hose induction therapy failed received teniposide
igure 5. Effect of allogeneic BMT compared with chemotherapy
n EFS from the time of relapse. Descriptive curves were obtained
rom a Mantel-Byar analysis stratiﬁed for duration of ﬁrst remis-
ion, site of relapse, and age. Because of the small number of events
eyond 4 years, the dotted lines indicate the cumulative results
eyond this time. Reprinted with permission.12
831
(
d
r
i
t
s
C
m
i
p
m
y
c
w
S
c
o
r
d
p
R
c
1
c
T
C
n
t
h
b
t
n
t
T
p
v
i
c
h
l

g
m
(
L
f
g
s
C
o
t
i
r
r
a
R
F
o
a
o
4
t
F
a
3
T. Hahn et al.
8VM-26) and cytosine arabinoside (Ara-C) for rein-
uction. Eleven patients underwent an HLA-matched
elated (n  4) or unrelated (n  7) allogeneic BMT
n CR1. Ten patients received consolidation chemo-
herapy (n  6) or consolidation chemotherapy plus
alvage allogeneic BMT in second CR (CR2; n  4).
onditioning regimens consisted of cyclophospha-
ide (Cy) or etoposide (VP) plus total body
rradiation (TBI; 1200 cGy in 6 fractions); GVHD
rophylaxis consisted of cyclosporine (CSA) and
ethotrexate (MTX). At a median follow-up of 3.4
ears in the BMT in CR1 group and 2.2 years in the
hemotherapy/BMT in CR2 group, the 4-year EFS
as 53% versus 33%, respectively (P value not stated).
econd or Greater Complete Remission
Barrett et al. [11] reported a retrospective matched
ase-control study of pediatric (19 years at the time
f treatment) ALL patients in CR2 that compared 376
elated HLA-matched allogeneic BMT patients (un-
erwent transplantation between 1983 and 1991) re-
orted to the International Bone Marrow Transplant
egistry with 540 patients treated on 4 Pediatric On-
ology Group chemotherapy trials between 1983 and
991. From these 2 groups, 255 matched pairs were
hosen with identical inclusion and exclusion criteria.
he pairs were matched on prognostic factors (age at
igure 6. Effect of autologous BMT compared with chemotherapy
n EFS from time of relapse. Descriptive curves were obtained from
Mantel-Byar analysis stratiﬁed for duration of ﬁrst remission, site
f relapse, and age. Because of the small number of events beyond
years, the dotted lines indicate the cumulative results beyond this
ime. Reprinted with permission.12R2, WBC at diagnosis, duration of CR1, and immu- r
32ophenotype), and the study accounted for time-to-
ransplantation bias (the chemotherapy group patient
ad to survive in CR at least as long as the time
etween CR2 and BMT in the matched BMT pa-
ient).
Leukemia-free survival (LFS) at 5 years was sig-
iﬁcantly higher in the BMT group compared with
he chemotherapy group (40% versus 17%; P .001).
his result was similar to that in the unmatched com-
arison of the BMT and chemotherapy cohorts (36%
ersus 16%; P  .001). The risk of relapse was signif-
cantly lower in the BMT group compared with the
hemotherapy group (45% versus 80%; P  .001);
owever, the TRM within 5 years was signiﬁcantly
ower in the chemotherapy group (14% versus 27%; P
.001). The 5-year LFS was higher in the BMT
roup for both the early relapse group (CR1 36
onths; 35% versus 10%) and the late relapse group
CR1 36 months; 53% versus 32%; Figure 4). The
FS results did not vary when compared across dif-
erent subgroups of prognostic factors: the BMT
roup fared better than the chemotherapy group in all
ubgroup comparisons, including the duration of
R1.
Wheeler et al. [12] retrospectively examined the
utcomes of 432 children diagnosed with ALL be-
ween 1985 and 1990 who received induction therapy
n the MRC UKALL X trial and who subsequently
elapsed (before October 1993), achieved a CR2 after
einduction therapy (not randomized or standardized),
nd received maintenance chemotherapy or BMT.
elated donor SCT was performed at 22 centers,
igure 7. DFS rates (SE) in groups of patients who underwent an
llogeneic BMT (AlloBMT; 57 patients), autologous BMT (ABMT;
6 patients), or chemotherapy (CHEMO; 230 patients) in second
emission after a medullary relapse. Reprinted with permission.13
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Cytotoxic Therapy with Hematopoietic SCT for ALL
Butologous BMT at 18 centers, and URD SCT at 3
enters. Comparisons were made between allogeneic
MT (n  110; including 83 with related donors and
7 with URDs), chemotherapy (n  261), and autol-
gous BMT (n  61). EFS at 4 years adjusted for
rognostic factors (CR1 duration and site of relapse)
nd time-to-transplantation bias showed marginal sig-
iﬁcance in favor of allogeneic transplantation over
hemotherapy (42.6% versus 28.2%; P  .05; Figure
). EFS at 4 years adjusted for prognostic factors (CR1
uration and site of relapse) and time-to-transplanta-
ion bias showed no difference between chemotherapy
nd autologous BMT (27.5% versus 35.4%, respec-
ively; P  .10; Figure 6).
Uderzo et al. [13] performed a retrospective case-
ontrol study of related HLA-matched allogeneic
MT (n  57) versus maintenance chemotherapy (n
230) in pediatric (18 years at the time of BMT)
atients with ALL treated in CR2 selected from 27
IEOP or Gruppo Italiano Trapianto di Midollo Os-
eo centers. All patients had relapsed between 1980
nd 1989. No matching on prognostic variables was
onducted to evaluate the relationship and effect of
rognostic factors in the multivariate model. The
-year DFS adjusted for time-to-transplantation bias
as higher in the allogeneic BMT than the chemo-
herapy group (41.4%  6.6% versus 21.7%  3.7%;
o P value stated; Figure 7). Multivariate analysis of
rognostic factors found only duration of CR1 to be
igniﬁcantly related to outcome. For patients with an
arly relapse (CR1 duration 30 months), allogeneic
MT had a signiﬁcantly improved outcome compared
ith chemotherapy (RR  0.45; P  .002; 3-year
djusted DFS, 33.4% versus 16.1%). For patients with
late relapse (CR1 duration 30 months), there was
o difference in the failure rate between the allogeneic
MT and chemotherapy groups (RR  0.94; P  .92;
-year adjusted DFS, 54.7% versus 39.6%).
Harrison et al. [14] performed a prospective non-
andomized trial (MRC UKALL R1) from 1991 to
995 comparing the outcomes of pediatric (15 years
t diagnosis) patients with ALL in CR2 who had
elated HLA-matched donors (n 67) with those who
id not have donors (n  139). Most patients had
reviously been treated on the MRC UKALL X and
I trials, but none had received a BMT in CR1.
nadjusted EFS at 5 years was not signiﬁcantly dif-
erent between the patients who did and did not have
elated donors (45% versus 45%; P  .10). After
djustment for prognostic factors, EFS at 8 years re-
ulted in an 8% difference between the donor and
o-donor groups and favored the donor group (45%
ersus 37%; P  .10). According to the actual treat-
ent received, EFS at 5 years was 46% for related
llogeneic BMT (n  63), 54% for unrelated alloge-
eic BMT (n  41), and 43% for chemotherapy (n 
10) or autologous BMT (n  15). Adjusting for l
B&MTime-to-transplantation bias and prognostic factors,
he odds ratio for any event in the related/unrelated
llogeneic BMT group compared with the chemo-
herapy/autologous BMT group was 0.94 (95% CI,
.64-1.39; P  .10).
Schroeder et al. [15] retrospectively selected all
elated allogeneic BMT pediatric (16 years at diag-
osis) patients treated for ALL in CR2 (n  75) from
he Nordic population-based registry diagnosed be-
ween 1981 and 1992 and compared them with 150
ontrols randomly selected from the same registry in
he same time period who received maintenance che-
otherapy in CR2. Controls were matched on time
eriod of diagnosis, immunophenotype, site of re-
apse, initial risk group, sex, and relapse 6 or 6
onths after completing therapy, and adjustment was
ade for time-to-transplantation bias. EFS was sig-
iﬁcantly better for the BMT group (40% versus
3%; P  .02). The BMT group also had signiﬁcantly
mproved EFS for patients who had early (6 months
rom completion of therapy) marrow relapse (32%
ersus 11%; P .01) and marginal signiﬁcance toward
mproved EFS for patients who had late marrow re-
apse (42% versus 29%; P  .05).
Borgmann et al. [16] reported the results of all
hildren (19 years at the time of relapse) with ALL
n CR2 after an isolated (one site; n  159) or com-
ined (one site; n  6) extramedullary relapse
reated prospectively on Relapsed ALL (ALL-REZ
Rezidiven]) BFM multicenter trials (the number of
enters was not stated) between 1983 and 1993 by
sing allogeneic BMT (n  17), autologous BMT (n
14), or chemotherapy (n  134). There was no
tatistically signiﬁcant difference between the autolo-
ous and allogeneic BMT groups; therefore, the re-
ults are presented as a combined BMT group. Un-
djusted EFS at 5 years was higher for the
hemotherapy group compared with the BMT group
47% versus 36%; P  .05). After adjustment for
ime-to-transplantation bias, there was a signiﬁcantly
igher EFS in the chemotherapy group (50% versus
6%; P  .05). No multivariate analyses or adjust-
ents were made for other prognostic factors.
Borgmann et al. [17] performed a matched-pair
nalysis of pediatric (18 years) patients with relapsed
LL treated in the multicenter (the number of centers
as not stated) ALL-REZ BFM trial from 1983 to
994 (there is some overlap with Borgman et al. [16],
resented in the previous paragraph). Of 95 patients
reated in CR2 with an URD BMT and 1188 patients
reated in CR2 with chemotherapy and radiation ther-
py, 81 pairs were chosen that matched identically for
ite of relapse and immunophenotype and as closely as
ossible on CR1 duration, age, diagnosis date, and
BC at relapse. All patients were intermediate risk or
igh risk. Intermediate risk was deﬁned as: (1) T or B
ineage with an isolated extramedullary (IE) relapse
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8ccurring very early (18 months from diagnosis) or
arly (18 months from diagnosis but 6 months
rom therapy cessation), (2) B lineage with combined
one marrow (BM) relapse occurring early or late (6
onths from therapy cessation), or (3) B lineage with
solated BMT relapse occurring late. High risk was
eﬁned as: (1) T lineage with isolated BM or com-
ined BM relapse occurring at any time, (2) B lineage
ith combined BM relapse occurring very early, or (3)
lineage with isolated BM relapse occurring very
arly or early. The HLA-matching status of the URD
MT group was matched (64%), unknown (20%),
-antigen class I or II mismatch (12%), and 2-antigen
lass I mismatch (4%). Conditioning regimens varied;
owever, 70% received Cy or VP  TBI, and 95% of
ll patients had TBI-containing regimens. T-cell de-
letion was used in 84% of URD BMTs. Most URD
MT patients received CSA  MTX  methylpred-
isolone as additional GVHD prophylaxis. At a me-
ian follow-up of 4.1 years from CR2 in the URD
MT group and 7.9 years from CR2 in the chemo-
herapy group, the 5-year EFS was signiﬁcantly better
n the URD BMT group (42% versus 17%; P .001).
fter stratiﬁcation by risk, there was no signiﬁcant
ifference in 5-year EFS between the URD BMT and
hemotherapy groups in the intermediate-risk group
49% versus 39%, respectively; P  .105); however,
here was a signiﬁcantly better 5-year EFS in the
RD BMT group (44% versus 0%; P  .0001).
Hoogerbrugge et al. [18] conducted a retrospec-
ive case-control study comparing children (upper age
imit not stated) with ALL in CR2 treated at a single
utch center between 1982 and 1991 with a related
LA-matched allogeneic BMT (n  25) or mainte-
ance chemotherapy (n  97). Cases were matched
ith controls on site of relapse and duration of CR1,
nd adjustment was made for time-to-transplantation
ias. All patients were initially treated with intensive
hemotherapy regimens (3 or more drugs for induc-
ion therapy). There was a nonsigniﬁcant LFS advan-
age in favor of the BMT group (4-year LFS, 44%
ersus 24%; hazard ratio, 0.76; P  .43). After strat-
ﬁcation by site of relapse, there was no difference in
FS between the BMT and chemotherapy groups for
reatment of isolated BM relapses (n  70; LFS haz-
rd ratio, 0.98; P .95). There was also no statistically
igniﬁcant difference in LFS between the BMT and
hemotherapy groups for the treatment of an isolated
NS relapse (n  52; LFS hazard ratio, 0.40; P 
23).
Borgmann et al. [19] retrospectively compared pe-
iatric patients with ALL in CR2 after an IE (n 16),
solated BM (n  76), or combined (n  12) relapse
ho received autologous BMT or chemotherapy as
herapy in BFM multicenter trials between 1983 and
994. Fifty-two matched pairs were chosen from BFM
rial patients who received chemotherapy (n 682) or s
34utologous BMT (n  66). The pairs were matched
n prognostic factors (age at diagnosis, sex, immuno-
henotype, site of relapse, and duration of CR1) and
djusted for time-to-transplantation bias. EFS at 9
ears was not signiﬁcantly different between the che-
otherapy and BMT patient groups (32% versus
6%, respectively; P  .10). No signiﬁcant difference
n EFS was found between the chemotherapy and
MT groups when stratiﬁed by early (36 months)
ersus late (36 months) relapse.
Messina et al. [20] compared treatment with au-
ologous BMT (n 19) versus chemotherapy (n 41)
t 10 AIEOP centers for pediatric (upper age limit not
tated) patients with ALL in CR2 after an early iso-
ated CNS relapse. Early relapse was deﬁned as dura-
ion of CR133 months. All ALL patients treated for
solated CNS relapse at 10 AIEOP centers from 1986
o 1992 were included in this study, except for 9
elated allogeneic BMT patients who were noted in
he report to be too small a group for comparison.
ultivariate analysis adjusting for time-to-transplan-
ation bias and prognostic factors (duration of CR1,
ge, WBC at diagnosis, immunophenotype, and sex)
ound a signiﬁcantly improved 5-year DFS in the
utologous BMT group (56.3% versus 12.6%; P 
01). Only treatment (autologous BMT versus chemo-
herapy) and WBC at diagnosis (50 000 versus
50 000/L) were signiﬁcantly associated with DFS in
he multivariate model.
Boulad et al. [21] prospectively evaluated pediatric
18 years at diagnosis) patients with ALL in CR2
fter a medullary relapse (between 1979 and 1992)
ho received a related HLA-matched allogeneic
MT (n  37) or chemotherapy (n  29) at a single
S center. Time-to-transplantation bias was adjusted
or in the analyses of survival (all patients included had
o survive in CR2 for a minimum of 3 months). DFS
t 5 years adjusted only for time-to-transplantation
ias was signiﬁcantly higher in the BMT group (62%
ersus 26%; P  .03). Adjusting for the confounding
actors of age at diagnosis, leukocyte count at diagno-
is, duration of CR1, and prior treatment intensity
ielded a hazard ratio of 2.84 (95% CI, 1.78-3.91; P
01) for the chemotherapy group when compared with
he BMT group. When stratiﬁed into high- versus
verage-/low-risk groups by Children’s Cancer Group
riteria, DFS for the BMT group remained signiﬁ-
antly better than that for the chemotherapy group for
oth risk categories.
Feig et al. [22] prospectively enrolled 96 pediatric
21 years at diagnosis) patients with ALL on a mul-
icenter (number of centers not stated) protocol (Chil-
ren’s Cancer Group 1884) who experienced a med-
llary relapse while on or within 1 year of completing
nduction therapy (the range of years patients were
nrolled was not stated). Sixty-two of these children
ubsequently achieved CR2 and were treated with
Table 5. Comparison of Patient Characteristics and Outcomes from Articles Included in the Autologous SCT Section
Reference
Quality and
Strength of
Evidence*
Patient
Populations
No. of
Patients
Upper Limit (Median)
Age at Time of
Transplantations (y)
Treatment-
Related
Mortality
Median
Follow-up
(mo) LFS/EFS/DFS
Significance:
LFS/EFS/DFS§ OS
Significance:
OS§
Purged autologous BMT
26 2 Italian multicenter BMT
trials
Total 154 8-y EFS Not significant Not stated Not compared
AIEOP protocols 55, 82,
87, and 88
CR2 98 21 (10) 9.7% 66 34.6%
CR >2 56 10.6%
27 2 Spanish multicenter
study
Total 55 6-y EFS P  .036 Not stated Not compared
Early Rlps 32 17 (8) 5% 76 37%
Late Rlps 23 56%
28 2 Single US center 51 18 (9) at diagnosis 9.8% 31 3-y EFS Not compared 3-y OS Not compared
53% 63%
29 2 Single US center (no
overlap with
reference 28, above)
Total 44 5-y EFS P  .0002 Not stated Not compared
CRI <24 mo 14 (4) 23% 28.5 0%
CRI 24 to <36 mo 33%
CRI >36 mo 65%
30 2 Italian AIEOP
multicenter BMT
trials
Total 75 5-y DFS P < .001 5-y OS Not compared
IE Rlps 19 19 (9) 9% Not stated 68.4% 31.7%
BM Rlps 56 13.1%
31 2 Spanish multicenter
study
Total 27 Overall DFS† Not stated Not stated Not compared
CRI 6 16 (6) 5.3%† 15† CR1 71%
CR2 13 CR2 46%
CR3 8
32 2 Single Swedish center 25 17 (8.6) 0% 50 Overall DFS Not compared Not stated Not compared
65%
33 2 Single US center 24 21 (9.5) 8.3% 41 2-y DFS Not compared 2-y OS Not compared
42% 54%
34 2 4 French centers Total 24 6 mo
CR >2 19 37 (13) 26% 14 Not stated Not compared Not stated Not compared
Rlps/PIF 5 13 (5) 0% 28
35 2 Single US center 23 18 (8.9) 4.3% 15.5 1-y DFS Not compared 1-y OS Not compared
29% 49%
36 2 German BFM front line,
BFM relapse
protocols
4-y EFS Not compared Not stated Not compared
22 17 (4.7) 9% Not stated 18%
37 2 AIEOP BMT trials 8702
and 8802, 8703, and
8803
2-y EFS Not compared Not stated Not compared
12 15 (5.6) at diagnosis 8.3% 24 80%
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8MT (11 related allogeneic, 1 unrelated allogeneic,
nd 7 autologous BMT) or chemotherapy (n  33).
en chemotherapy-treated patients relapsed before
he mean time to transplantation and were excluded
rom the analysis. EFS at 2 years adjusted for time-
o-transplantation bias was signiﬁcantly higher in the
MT group compared with the chemotherapy group
37% versus 18%; P  .017). Adjusting for the inten-
ity of prior chemotherapy regimens and the duration
f previous remission maintained the improved EFS
f BMT over chemotherapy (RR  2.59; P  .01).
Torres et al. [23] reported 76 pediatric (17 years
t diagnosis) patients with ALL in CR2 after BM
elapse treated in 1 of 4 Spanish centers from 1980 to
988 with a related HLA-matched allogeneic BMT (n
21) or, if no donor was available, chemotherapy (n
55). Adjustment was made for time-to-transplanta-
ion bias, but there was no adjustment for or multi-
ariate analysis of prognostic factors. DFS was signif-
cantly higher in the BMT group (47.1% versus 9%; P
.025).
Johnson et al. [24] described the outcomes of 45
ediatric (17 years) patients with ALL treated in
R2 with either a related allogeneic BMT (n 24) or
onventional maintenance chemotherapy (n  21;
hildren with no allogeneic donor were given treat-
ent on Children’s Cancer Group protocols) at a
ingle US center between 1976 and 1980. All patients
ad an isolated or combined BM relapse while receiv-
ng maintenance chemotherapy and were able to
chieve a CR2. The median duration of CR1 was 13
onths in the chemotherapy group and 26 months in
he BMT group. The conditioning regimen was Cy
BI, and GVHD prophylaxis consisted of MTX
lone. At a median follow-up of 33 months, the BMT
roup had a better OS (46% versus 10%; P not stated)
nd DFS (38% versus 5%; P  .002) than the che-
otherapy group.
Bacigalupo et al. [25] compared 17 children (13
ears at the time of treatment) with ALL in CR2 who
ere treated prospectively and received a related
LA-matched allogeneic BMT at one Italian center
ith 19 children who received standard consolidation
nd maintenance chemotherapy regimens at a second
talian center (the range of years patients were treated
as not stated). Patients in the BMT group had a
igniﬁcantly higher rate of DFS (58% versus 18%; P
.01) and OS (48% versus 22%; P  .04) compared
ith the chemotherapy group. No multivariate anal-
ses or adjustments were made for prognostic factors.
utologous Stem Cell Transplantation
Table 5 summarizes the grading criteria, study
opulations, patient characteristics, and outcomes
rom pediatric studies included in the autologous SCT
section. Evidence in this section is taken from self-Ta Re
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Cytotoxic Therapy with Hematopoietic SCT for ALL
Bescribed studies of pediatric populations, all of which
ncluded patients 21 years of age. Evidence is pre-
ented with the highest-quality studies ﬁrst; studies of
qual quality are presented in descending order with
he largest sample size ﬁrst.
Unpurged autologous SCT. There are no data pub-
ished for which at least half the study population was
reated with unpurged autologous SCT. The studies
ummarized in the next section include a minority
roportion of unpurged autologous SCT patients;
owever, most of the study populations received
urged grafts.
Purged autologous SCT. Messina et al. [26] per-
ormed a retrospective cohort study of the AIEOP
MT registry between 1984 and 1994. This study
xamined the outcomes of 154 pediatric (21 years at
MT) patients with ALL from 10 Italian pediatric
MT centers in CR 2 registered for autologous
MT by AIEOP. Criteria for autologous BMT were
1) a relapse within 30 months of diagnosis or high-
isk group at diagnosis or multiple relapses, (2) lack of
ny suitable matched donor, and (3) morphologic re-
ission before transplantation. Ninety-eight CR2 pa-
ients underwent autologous BMT, 65 had an isolated
r combined BM relapse (n  46 and n  19, respec-
ively), and 33 had an IE relapse. Mafosfamide or
incristine prednisolone were used for in vitro purg-
ng in 45 of 65 isolated or combined BM relapse
atients and 21 of 33 IE relapse patients; 32 received
npurged grafts. The median duration of CR1 for this
roup was 25 months, and median follow-up was 66
onths. Fifty-six patients underwent autologous
MT, 38 after 2 or more isolated and/or combined
M relapses and 18 after 2 or more IE relapses (CR
2). In vitro purging was used in 25 of 38 BM and 8
f 18 IE relapse patients. The median duration of CR1
or this group was 30 months, and the median fol-
ow-up was 66 months. BMT conditioning regimens
onsisted of busulfan (Bu)  Cy (n  42), vincristine
Cy  TBI (n  42), other TBI-containing regi-
ens (n  39), or other chemotherapy-based regi-
ens (n  31).
Of 154 patients, 15 (9.7%) children died of TRM:
(8.4%) in the CR2 group and 7 (12%) in the CR 2
roup. The 8-year EFS for patients who underwent
ransplantation in CR2 and CR 2 were 34.6% and
0.6%, respectively (P  .11). The 8-year EFS for the
M relapse group and the IE group was 15.2% and
9.9%, respectively (P  .0011). Within the CR2
roup, the 8-year EFS was signiﬁcantly inﬂuenced by
ite of relapse: 18.2% BM versus 68.5% IE (P 
0001). The CR 2 group was not signiﬁcantly inﬂu-
nced by relapse site, purging, TBI conditioning reg-
men, or duration of CR1.
Maldonado et al. [27] performed a 3-center Span-
sh study of 55 pediatric (18 years at BMT) patients
ith ALL from 1987 to 1994. All patients were in 
B&MTR2 when they received their monoclonal antibody
mAb)–purged BM by using complement (n  48) or
agnetic beads (n  7); common ALL (c-ALL) and
-lineage ALL immunophenotypes were purged with
nti-CD9, anti-CD10, anti-CD19, and anti-CD20 (n
not stated), and T-lineage ALL was purged with
nti-CD2, anti-CD3, anti-CD4, anti-CD6, and anti-
D8 (n  not stated). Treatment before transplanta-
ion referral differed by center. The median duration
f CR1 was 27 months. Of 32 children with an early
elapse (30 months from diagnosis), 14 patients had
n IE relapse; of the late relapse group, 18 had an
solated BM relapse, and 5 had a combined BM re-
apse. Conditioning regimens were Cy  Ara-C 
BI (n  23), VP  Cy  TBI (n  5), Cy  TBI
n  21), or Bu  Cy  VP (n  6). Three patients
5%) died of TRM. At a median follow-up of 76
onths, the 6-year EFS was 45%: 56.5% for the late
elapse group and 37% for the early relapse group.
one of the following factors was signiﬁcant for
-year EFS in the multivariate analysis: relapse site
IE, 43%; BM with or without another site, 46%),
R1 duration (30 months, 37%; 30 months,
6%), conditioning regimen (Cy  TBI, 28%; Cy 
BI  Ara-C or VP, 60%), or interval between re-
apse and autologous BMT (6 months, 47%; 6
onths, 47%).
Billett et al. [28] performed a prospectively de-
igned phase II study of autologous BMT in 51
ediatric (18 years at diagnosis) patients with ALL
t a single US center between 1980 and 1991. All
atients lacked a suitable donor for allogeneic BMT
nd were in CR 2, with CR1 lasting 24 months
median, 38 months). Five patients had previous IE
isease, and 22 had previous combined BM and
xtramedullary disease. Twenty patients with CR1
24 months were excluded and are presented in
allan et al. [29] below. All received BM that was
urged in vitro with both anti-CD9 and -CD10
Abs (n  46) or a single mAb (n  5) and received
aried conditioning regimen combinations includ-
ng Ara-C, VM-26, Cy, and TBI, as well as radiation
herapy to extramedullary sites. Five (9.8%) patients
ied of TRM, and 18 (35.3%) patients relapsed
ithin a median time of 8 months. At a median
ollow-up of 31 months, the 3-year EFS and LFS
ere 53% and 58%, respectively, and the OS rate
as 63%, 55%, and 47% at 3, 4, and 7 years,
espectively. The factors examined for association
ith EFS and LFS in the multivariate analysis were
he longest duration of CR before autologous BMT,
he duration of CR before autologous BMT, cell
ose per kilogram, prior therapy, year of diagnosis,
einduction regimen, and Ara-C dose before BMT.
he duration of the longest CR before autologous
MT (P  .07) and the CR duration before BMT (P
.07) showed marginal signiﬁcance in predicting
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8FS. The only signiﬁcant predictor of LFS was cell
ose per kilogram (P  .025). The duration of the
ongest CR (P  .06) showed marginal signiﬁcance.
Sallan et al. [29] presented the results of 44 pedi-
tric (18 years at the time of BMT) patients with
elapsed (n  43) or refractory (n  1) ALL treated
ith a purged autologous BMT at a single US center
rom 1980 to 1988. BMT was performed in CR1 (n 
), CR2 (n  27), CR3 (n  15), or CR4 (n  1).
atients with T-lineage ALL, HLA-compatible do-
ors, and inability to achieve CR with chemotherapy
lone were excluded. The median duration of CR1
as 29 months. The sites of ﬁrst relapse were isolated
M (n  27), IE (n  10), or combined BM (n  6).
M was purged with anti-CD10 (n  12), anti-CD9
n  1), or both (n  31) mAbs. The conditioning
egimen consisted of Cy  Ara-C  VM-26  TBI
850 cGy in a single dose to 1400 cGy in 8 fractions)
ith or without asparaginase. At a median follow-up
f 28.5 months, the 5-year EFS was 29%. Five-year
FS signiﬁcantly varied by CR1 duration: 0% for24
onths versus 33% for 24 to 36 months versus 65%
or 36 months (P  .0002).
Colleselli et al. [30] performed a retrospective co-
ort study of 9 Italian centers that reported data to the
IEOP BMT Registry between 1984 and 1992. The
tudy included 75 pediatric (20 years at BMT) pa-
ients with ALL who underwent an autologous BMT
n CR2 after a single IE relapse (n  19) or a single
M relapse with or without another site (n 56). BMT
onditioning regimens varied by center; 43 (57%) re-
eived TBI-based regimens. BM was unpurged (n 18)
r was purged with mafosfamide (n  43) or vincristine
methylprednisolone (n  14). Seven (9%) patients
ied of TRM; 44 (58.6%) relapsed after autologous
MT. Twenty-four (32%) of 75 patients were in con-
inuous complete remission at a median of 30 months.
he median follow-up of survivors was not stated.
he 5-year OS and DFS were 31.7% and 27.8%,
espectively. The study examined the site of relapse,
uration of CR1, duration of CR2 after autologous
MT, purging of BM, and TBI as a conditioning
egimen, but only relapse site statistically inﬂuenced
FS (68.4% IE versus 13.1% BM; P  .001).
Canals et al. [31] reported the results of a Spanish
etrospective multicenter (number of centers not
tated) cohort study of 27 pediatric (17 years at
MT) patients with ALL who received purged autol-
gous BMT between 1991 and 1994. Patient BM was
arvested and immunomagnetically purged ex vivo at
he same laboratory; B-lineage ALL BM (n  31) was
urged with anti-CD10, -CD19, and -CD20 mAbs,
nd T-lineage ALL BM (n  6) was purged with
nti-CD4, -CD5, -CD6, -CD8, and -CD28 mAbs.
wenty-seven (73%) patients were autografted in
R1 (n  6), CR2 (n  13), or CR 2 (n  8). Forhe CR2 group, the duration of CR1 was 24 months p
38n  9) or 24 months (n  4); the CR1 duration for
he CR 2 group was not stated. The site of ﬁrst
elapse was not stated. Conditioning regimens were
BI based with different chemotherapy combinations.
ll patients autografted in CR 3 relapsed early (not
eﬁned in article) after autologous BMT. One (5.3%)
atient died of TRM; 7 (36.8%) relapsed within a
edian of 3 months, and 11 (57.8%) remained in CR.
t a median follow-up of 15 months, DFS was 71%
nd 46% for the CR1 and CR2 groups, respectively.
Lonnerholm et al. [32] reported the results of a
wedish single-center study of 25 consecutive pediatric
17 years at BMT) patients with ALL with purged
utologous BMT between 1985 and 1991. Two high-
isk CR1 patients and 23 CR 2 patients received
utologous BMT. The median time from diagnosis to
rst relapse was 2.8 years; the duration of CR1 was not
tated in the article. Relapse sites included isolated
M (n  14), IE (n  7), or combined BM (n  2).
arvested marrow was purged by cytolytic mAbs plus
abbit complement; pre–B-lineage ALL was purged
ith anti-CD10 with or without anti-CD9 antibodies
n  23), and T lineage was purged with anti-CD7
ntibodies (n  2). The conditioning regimen con-
isted of Cy  vincristine  Ara-C  daunorubicin 
eniposide prednisoloneTBI (single fraction, 750
Gy) for all patients. No patients died of TRM. The 2
atients who underwent transplantation in CR1 were in
ontinuous complete remission 5.3 and 3.4 years after
utologous BMT. Sixteen (70%) of 23 children who
nderwent transplantation in CR 2 are in continuous
omplete remission at a median follow-up of 50 months.
verall DFS for the entire group is 65%.
Houtenbos et al. [33] performed a prospective US
ingle-center cohort study of 24 pediatric (21 years
t BMT) patients with ALL who received purged
utologous BMT between 1990 and 1996. Patients
ad no suitable related or unrelated allogeneic donor
nd had high-risk ALL in either CR1 (n  5) or CR
2 (n  19) when they underwent transplantation.
igh-risk ALL in CR1 was deﬁned as age 1 year,
iagnostic WBC 250 000/L, 6 weeks to attain
R1, or chromosomal abnormalities [t(4;11) or t(9;
2)]. For the CR 2 group, the median CR1 duration
as 34 months, and relapse sites were isolated BM (n
11), IE (n  3), or combination BM (n  5). All
ere conditioned with VP  Cy  TBI  verapamil,
nd their CR BM was purged ex vivo with verapamil
incristine  VP. The patients were divided into 3
ohorts for posttransplantation therapy. Cohort 1 (n
4) received CSA alone, cohort 2 (n  7) received
SA  -interferon, and cohort 3 (n  13) received
SA, 6 alternating cycles of -interferon  chemo-
herapy, and 6 additional cycles of chemotherapy fol-
owed by granulocyte colony-stimulating factor (post-
ransplantation immune chemotherapy). Two (8.3%)
atients died of TRM. At a median follow-up of 41
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Cytotoxic Therapy with Hematopoietic SCT for ALL
Bonths, the 2-year DFS and OS were 42% and 54%,
espectively. Patients receiving posttransplantation
mmune chemotherapy versus immunotherapy alone
CSA with or without -interferon) had signiﬁcantly
etter EFS and OS probabilities (P  .008 and P 
06, respectively). None of the prognostic factors ex-
mined, including the duration of CR1 and CR 1,
elapse site, timing of relapse, or chemotherapy, was
ssociated with DFS or OS.
Pico et al. [34] performed a prospective phase II
tudy at 4 French centers between 1982 and 1985 of
urged autologous BMT in 24 patients with ALL (88%
18 years at BMT) who lacked an HLA-matched allo-
eneic donor. Nineteen patients were in CR 2, and 5
atients had primary refractory or relapsed disease.
ites of prior relapse were IE (n  11), isolated BM (n
10), or BM and other (n  4) [editorial note:
umbers do not add up but are given as stated in the
rticle]. All patients received carmustine  Ara-C 
y  6-thioguanine as their conditioning regimen.
wenty-one patients received marrow purged in vitro
ith either mafosfamide (n  17) or anti-cALLa
common acute lymphoblastic leukemia antigen) mAb
nd complement (n 4); 3 patients received unpurged
M. Fourteen (74%) of 19 CR 2 patients died of
isease before 12 months after BMT (n  9) or of
RM (n  5), and 4 (80%) of 5 progressive disease
atients died of disease before 12 months after BMT.
Ramsay et al. [35] reported the results of a single
S center prospective phase II study of 23 pediatric
17 years at diagnosis) patients with ALL in CR 2
reated with purged autologous BMT between 1982
nd 1984. Sites of prior relapse were isolated BM (n
9) or BM  extramedullary (n  4). BM was purged
ith mAbs (anti-CD24, anti-CD9, and anti-CD10)
nd rabbit complement. All patients received Cy 
BI as the conditioning regimen. The median CR1
urations for the CR2 and CR 2 groups were 8.7
nd 16.7 months, respectively. One patient (4.3%)
ied of TRM. At a median follow-up of 15.5 months,
he 1-year OS and DFS were 49% and 29%,
espectively.
Schmid et al. [36] performed a phase II study of
urged autologous BMT in 22 high-risk pediatric (17
ears at diagnosis) patients with ALL at a single German
enter between 1987 and 1992. Remission status was
R2 (n  13), CR3 (n  8), or CR4 (n  1). Sites of
elapse were isolated BM (n  18), IE (n  3), or
ombined BM (n 1); the median duration of CR1 was
1 months. Patients received VP  TBI for condition-
ng and were infused with mAb-purged BM; common
LL and B-cell ALL BM received anti-CD10, -CD19,
nd -CD24 (n 18), and T-cell BM received anti-CD2,
CD3, -CD5, and -CD7 (n  4). Two patients (9%)
ied of TRM. The median follow-up of surviving pa-
ients was not stated. The 4-year EFS was 18%, and the
robability of relapse was 80%. m
B&MTRossetti et al. [37] reported the results of an Italian
ingle-center study in which 12 pediatric (15 years at
iagnosis) patients with early IE (10 CNS and 2 tes-
icular) relapsed ALL underwent autologous BMT
etween 1987 and 1991. Early relapse was deﬁned as
elapse occurring during chemotherapy or within 6
onths of chemotherapy cessation. This study exam-
ned the toxicity and efﬁcacy of the conditioning reg-
men Ara-C  TBI (1440 cGy) before autologous
MT. All ﬁrst-line treatments were administered ac-
ording to AIEOP cooperative protocols (intermedi-
te risk, 8702 and 8802; high risk, 8703 and 8803).
ine patients received mafosfamide-purged BM, and
he last 3 patients received unpurged BM. One patient
8.3%) died of TRM. Three patients (25%) died due
o BM relapse occurring 1.5, 4, and 5 months after
utologous BMT. At a median follow-up of 24
onths, EFS was 80%.
Balduzzi et al. [38] reported the results of a pro-
pective Italian single-center study performed of
urged autologous PBSCT for 11 of 12 consecutive
ediatric (18 years at BMT) patients with B-lineage
recursor ALL in CR2 after IE (n  2), isolated BM
n 6), or combined BM (n 3) late relapse (median,
7 months; range, 31-51 months after the onset of
R1) between 1997 and 1999. One patient did not
obilize enough peripheral blood stem cells, under-
ent an unmanipulated autologous BMT, and is not
ncluded in the analysis. All 11 patients received ﬁrst-
ine therapy according to either the LLA-91 or
LA-95 AIEOP protocol and received the same con-
itioning regimen of VPCyTBI. Peripheral blood
tem cells were purged in vitro with mAbs (anti-CD11b
nd -19). No patients died of TRM. At a median
ollow-up of 29 months, the 2-year EFS was 89%.
ne patient (9%) relapsed and died after autologous
BSCT, but the remaining 10 were alive and in CR.
he one patient who did not mobilize enough CD34
ells underwent unpurged autologous BMT and died
f relapse.
urged and Unpurged Autologous Stem Cell
ransplantation
The following study consisted of 70% pediatric
atients: Grañena et al. [39-40] reported the results of
atients with ALL (52% of purged and 57% of un-
urged groups were 15 years at the time of BMT)
ho received a purged (n  52) or unpurged (n  23)
utologous BMT at 3 Spanish centers from 1987 to
993. Remission states for purged BMT patients were
8.1% for CR1, 46.2% for CR2, and 5.7% for CR3.
emission states for unpurged BMT patients were
4.8% for CR1, 47.8% for CR2, and 17.3% for CR
3. Prior sites of relapse and duration of CR1 were
ot stated in the article. If the leukemia immunophe-
otype was known at diagnosis, then the harvested
arrow was purged with anti–T-cell (CD2, CD3,
839
Table 6. Comparison of Patient Characteristics and Outcomes from Articles Included in the Related Donor Allogeneic SCT Section
Reference
Quality and
Strength of
Evidence*
Patient
Populations
No. of
Patients
Upper Limit (Median)
Age at Time of
Transplantation (y)
Treatment-
Related
Mortality
Median
Follow-Up
(mo) LFS/EFS/DFS
Significance:
LFS/EFS/DFS‡ OS
Significance:
OS‡
Related donor
41 2 IBMTR study Total 690 Overall 5-y LFS P < .02† Not stated Not compared
CR1 <16 y 56 15 (13) 18% 21 56%
CR1 > 16 y 243 48 (24) 37% 39%
CR2 391 49 (15) 36% 26%
42 2 Survey of 14 US
centers
Total 213 45.7 (10.7) Not stated Not stated 3-y DFS Not compared Not stated Not compared
38%
43 2 Multicenter
trials of BFM
Relapse Study
Group
Total 169
CR2 136
CR3 33
15 (4)
13 (4)
13%
30%
63
44
6-y EFS
49%
48%
Not significant Not stated Not compared
44 2 Single Swedish
center
Total 112§ Day 100 Not stated Not compared 5-y P  .009
cGVHD 31 17 (9)¶ 9%¶ 84¶ 76%
No cGVHD 69 45%
45 2 Single US center Total 59 5-y 5-y EFS Not stated Not stated Not compared
CR2 31 18 (8) 23% 61 64%
CR3 12 18 (10) 33% 64 42%
CR4 or Rlps 16 18 (9) 13% 74 23%
46 2 Multicenter
study AIEOP
protocols 87,
88, 91 and 95,
and others
Total 40
CR1 13
CR2 27
18(9)
1 yr
8%
19%
36
3-y DFS
85%
56%
Not significant Not stated Not compared
47 2 Single US center Overall 10-y EFS Not compared 10-y Not compared
CR2 30 42 (10) 13% 47 61% 62%
48 2 Multicenter
study of SFGM
Day 100 4-y DFS Not compared 4-y Not compared
Total 21 4 (2.3) 0% 47 61.1% 68.6%
CR1 15 61.9% 72.2%
49 2 Pediatric
Oncology
Group 32 US
centers
Total 297
BMT 42
21 (not stated) at
diagnosis
Overall
41%
Not stated Not stated Not compared Not stated Not compared
50 2 2 US centers Overall 5-y EFS Not compared Not stated Not compared
Total 41 19 (8) 30% 98 59%
CR2 27 50%
CR3 or Rlps 14
T
.H
ahn
et
al.
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Table 6. Continued
Reference
Quality and
Strength of
Evidence*
Patient
Populations
No. of
Patients
Upper Limit (Median)
Age at Time of
Transplantation (y)
Treatment-
Related
Mortality
Median
Follow-up
(mo) LFS/EFS/DFS
Significance:
LFS/EFS/DFS OS
Significance:
OS
51 2 Single US center Day 100 5-y DFS Not compared Not stated Not compared
CR2 57 17 (not stated) 25% 48 40%
52 2 Single US center Total 52 3-y EFS Not compared Not stated Not compared
CR1 9 15 (8.5) Not stated 96 30%
CR2 34 36%
CR >3 9 22%
53 2 Single French
center FRALLE
or other
protocol
42
15 (not stated), mean
8.9
Day 100
26% 36
4-y EFS
53%
Not compared Not stated Not compared
54 2 French
multicenter
study
32 16 (13.5)
Day 100
12.5% 30
5-y LFS
84.4%
Not compared Not stated Not compared
55 2 Single US center CR2 or 3 20 1-y Overall Not compared Overall Not compared
16 (6.5) 30% 58 58% 58%
<70% Pediatric
patients
56# 2 Single US center Total 74 6-mo 5-y EFS Not compared Not stated Not compared
CR1 18 36 (24) 39% 57 42%
CR2 36 41 (14) 36% 54 43%
CR3/4 20 37 (12) 40% 72 25%/0%
57# 2 Single US center Total 48 Day 100 Overall LFS** Not stated** 6-y Not compared
HLA match 16 48 (12) 13% 46 38% 38%
HLA
mismatch 32
46 (10) 28%
LFS indicates leukemia-free survival; EFS, event-free survival; DFS, disease-free survival; OS, overall survival; IBMTR, International Bone Marrow Transplant Registry; CR1, ﬁrst complete remission;
BFM, Berlin-Frankfurt-Munster Study Group; CR2, second complete remission; CR3, third complete remission; cGVHD, chronic graft-versus-host disease; CR4, fourth complete remission; Rlps,
relapse; AIEOP, Associazione Italian di Ematologica ed Oncologica Pediatrica; SFGM, Société Française de Greffe de Moelle; BMT, bone marrow transplantation; CR3, third or greater complete
remission; FRALLE, French Multicenter Acute Lymphoblastic Leukemia Study.
*Quality and strength of evidence deﬁnitions are listed in Table 1.
†P  .02 comparing adult CR1 versus pediatric CR1 groups, P  .02 comparing adult CR1 and adult  pediatric CR2 groups, P  .003 comparing pediatric CR1 and adult  pediatric CR2 groups.
‡Not signiﬁcant: P  .01.
§A total of 72% of all 169 AML and ALL patients received grafts from related donors; 28% were from unrelated donors; the numbers for related versus unrelated donors are not stated for only ALL
patients.
Patients had to survive to day 90 after SCT to be at risk for chronic GVHD; therefore, the numbers do not add up to 112.
¶Includes 57 AML and 112 ALL patients.
#70% of patients met study criteria.
**LFS was 38% for 6/6, 50% for 5/6, 36% for 4/6, and 30% for 3/6 HLA-matched donor BMTs; P  .89.
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8D4, CD5, CD6, and CD8) or anti–B-cell (CD9,
D10, CD19, and CD20) mAbs; otherwise, the pa-
ient received unpurged marrow. Patients received Cy
TBI (1000-1400 cGy; n  63) or Bu  Cy (n  12)
s the conditioning regimen. At a median follow-up of
1 months, the 3-year DFS was 46.8% and 25.6% in
he purged and unpurged groups, respectively (P 
13). On multivariate analysis, there was an improved
FS in the purged group for patients 15 years (P 
04), 1 month to achieve CR1 (P  .02), and BMT
n CR1 (P  .016).
ELATED DONOR ALLOGENEIC STEM CELL
RANSPLANTATION
Table 6 summarizes the grading criteria, study
opulations, patient characteristics, and outcomes
rom pediatric studies included in the related alloge-
eic donor SCT section. Evidence in this section is
aken from self-described studies of pediatric popula-
ions, all of which included patients less than 21 years
f age. Evidence is presented with the highest-quality
tudies ﬁrst; studies of equal quality are presented in
escending order with the largest sample size ﬁrst.
Barrett et al. [41] conducted a study of pediatric
16 years at the time of BMT) and adult (age 16
ears at the time of BMT) patients with ALL reported
o the International Bone Marrow Transplant Regis-
ry by 107 centers between 1978 and 1986 who re-
eived an HLA-matched sibling allogeneic donor
MT in CR1 (n  299) or CR2 (n  391). Condi-
ioning regimens varied by center; however, 70% re-
eived Cy TBI, and 98% received a TBI-containing
egimen. GVHD prophylaxis also varied by center.
ites of prior relapse and duration of CR1 were not
tated in the article. The results of patients treated in
R1 were stratiﬁed by pediatric versus adult patients;
owever, the results of patients treated in CR2 were
ooled (56% were 16 years at the time of BMT).
dult ALL patients treated in CR1 (n  243) had a
igniﬁcantly lower 5-year LFS than that in pediatric
LL patients treated in CR1 (n  56; 39% versus
6%; P  .02). Patients who underwent transplanta-
ion in CR2 had a signiﬁcantly lower 5-year LFS
26%) than children (P  .0003) and adults (P  .02)
ho underwent transplantation in CR1. However,
hildren and adults who underwent transplantation in
R1 had a similar 5-year probability of relapse (27%
ersus 30%; P  not signiﬁcant). Multivariate analysis
f signiﬁcant risk factors for LFS in the adult CR1
roup were GVHD prophylaxis and donor-recipient
ex, and in the CR2 group, were age at the time of
MT (16 versus 16 years) and relapse occurring
hile receiving chemotherapy. There were too few
atients in the pediatric CR1 group to perform a
ultivariate analysis of LFS risk. r
42Weyman et al. [42] performed a retrospective sur-
ey of 14 US centers assessing 213 patients with ALL
70% were 16 years at the time of BMT) treated
etween 1981 and 1989 with a related allogeneic
MT (82% were HLA-matched siblings and condi-
ioned with Ara-C  TBI). Remission states were
2.1% for CR1, 57.5% for CR2, 15.5% for CR 3,
nd 15% for relapse 1. Sites of prior relapse and
uration of CR1 were not stated in the article. The
ra-C cumulative dose was either 24 or 36 g/m2, and
BI was either fractionated (1000-1575 cGy; n 197)
r delivered in a single dose (750-1000 cGy; n  16).
he TRM and median follow-up time were not stated
n the article. The 3-year DFS in all patients was 38%.
FS was higher in patients aged 0 to 11 years com-
ared with 11 years (52% versus 25%; P value not
tated) and in patients who underwent transplantation
n CR1 versus CR2 versus relapse (54% versus 41%
ersus 19%; P value not stated). Multivariate analysis
f risk factors for shorter DFS yielded age (as a cate-
orical variable; P  .0003), WBC at diagnosis (P 
028), disease status at BMT (P  .005), and donor
LA matching (P  .001) as statistically signiﬁcant.
Borgmann et al. [43] retrospectively identiﬁed 169
ediatric (19 years at the time of BMT) patients with
elapsed ALL enrolled in 4 consecutive multicenter
rials of the BFM Relapse Study Group between 1983
nd 1985 who received a BMT from a related donor.
atients underwent transplantation in CR2 (n  136)
r CR3 (n  33); the median duration of CR1 was 26
ersus 32 months, respectively (P  .001). Matched
elated BMT was recommended for all patients with
rst or subsequent BM relapse except for patients who
elapsed 4 years after CR1. Sites of ﬁrst relapse for
he CR2 group were isolated BM (n  100) or com-
ined BM (n  36); immunologic subtypes were B
recursor (n 119), T cell (n 12), or unclassiﬁed (n
5). Sites of second relapse for the CR3 group were
solated BM (n  26) or combined BM (n  7);
mmunologic subtypes were B cell (n  28), T cell (n
4), and unclassiﬁed (n  1). The conditioning
egimen was VP  Cy  TBI (1200 cGy) in 93% of
he CR2 and 82% of the CR3 groups; the remaining
atients received various chemotherapy-based combi-
ations. GVHD prophylaxis was not stated. TRM for
he CR2 versus CR3 groups was 13% versus 30%. At
median follow-up of 63 months, EFS at 6 years for
he CR2 group was 49% and varied by duration of
R1. The 6-year EFS for the CR3 group was 48% at
median follow-up of 44 months and was not signif-
cantly different from the CR2 group.
Gustafsson Jernberg et al. [44] retrospectively
tudied the effect of chronic GVHD on relapse and
urvival in 169 acute myeloid leukemia (AML; n 57)
nd ALL (n  112) pediatric (18 years at BMT)
atients from a single Swedish center treated with a
elated (n  122) or unrelated (n  57) SCT from
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Cytotoxic Therapy with Hematopoietic SCT for ALL
B980 to 2000. Patients with ALL underwent trans-
lantation in CR1 (n  26), CR2 (n  61), or CR 3
n  16) or when they were not in remission (n  9).
he duration of CR1 and prior sites of relapse were
ot stated. Conditioning regimens consisted of Cy 
BI (750-1000 cGy in a single fraction; n  124), Cy
TBI (fractionated 1200-1440 cGy; n 26), or Bu
y (n  19). GVHD prophylaxis consisted of CSA
lone, MTX alone, or CSA  MTX; in addition,
atients with unrelated or mismatched grafts received
ntithymocyte globulin (ATG), Orthoclone (Ortho
iotech Products, LP, Ravitan, NJ) anti-CD3 anti-
ody (OKT3; n  49), or in vitro T-cell depletion (n
10). The 5-year probability of chronic GVHD was
4%; the median time to occurrence was 181 days
fter SCT. Chronic GVHD reduced the probability
f relapse from 53% to 30% in ALL patients (P value
ot stated). At a median follow-up of 7 years, the OS
as signiﬁcantly improved in patients with ALL who
ad developed chronic GVHD compared with those
ho had not (76% versus 45%; P  .009).
Brochstein et al. [45] performed a prospective fea-
ibility trial of 97 pediatric (20 years at BMT) pa-
ients with ALL (n  59) or AML (n  38) treated
ith an HLA-matched sibling allogeneic BMT at a
ingle US center between 1979 and 1985. ALL pa-
ients were in CR2 (n  31), CR3 (n  12), CR4 (n 
), or relapse (n  14) at the time of BMT. The
edian duration of CR1 was 18.8 months in the CR2
roup, 22 months in the CR3 group, and 13 months in
he CR4/relapse group. Sites of prior relapse were not
tated. The conditioning regimen was Cy TBI (1320-
440 cGy); GVHDprophylaxis was eitherMTX or CSA
lone. At a median follow-up of 61, 64, and 74 months,
he 5-year EFS was 64%, 42%, and 23% in the CR2,
R3, and CR4/relapse groups, respectively (P value
ot stated).
Zecca et al. [46] performed a prospective multicenter
hase II study of thiotepaCyTBI as a conditioning
egimen in 40 consecutive pediatric (19 years at the
ime of BMT) patients with ALL in CR1 or CR2 who
eceived an HLA-identical sibling BMT from 1992
nd 1997 at 6 AIEOP BMT centers. Thirteen high-
isk patients underwent BMT in CR1; the median
ime from CR to BMT was 4.3 months. Indications
or BMT in CR1 varied between centers, but overlap-
ing criteria included unfavorable cytogenetics, resis-
ance to corticosteroids (1000 blasts per microliter
n peripheral blood after 7 days of prednisone), high
BC count at diagnosis, T-cell immunophenotype,
nd lack of remission at the end of the induction
hase. Out of the 27 patients who underwent trans-
lantation in CR2, relapse sites were isolated BM (n
0), combined BM (n 4), and IE (n 3); the median
ime from diagnosis to ﬁrst relapse was 28 months.
he preparatory regimen was thiotepa  Cy  TBI990 cGy in 3 fractions [n  4] or 1200 cGy in 6 i
B&MTractions [n  36]). GVHD prophylaxis consisted of
SA alone for all patients. Overall TRM was 15%:
% in the CR1 group versus 19% in the CR2 group (P
ot stated). At a median follow-up of 36 months, the
-year DFS was 65%: 85% in the CR1 group versus
6% in the CR2 group (P  not signiﬁcant). There
as no observed signiﬁcance on patient outcome for
he variables sex, age at diagnosis, age at BMT, WBC
ount at diagnosis, immunophenotype, interval from
R to transplantation, or GVHD.
Jamieson et al. [47] reported the results of a ret-
ospective analysis of 85 pediatric and adult patients
ith ALL treated in CR1 or CR2 with an HLA-
atched sibling allogeneic BMT at a single US center
etween 1987 and 2002. Most (71%) patients treated
n CR1 (n  55) were adults, and their results are
resented in the adult ALL review [3]. Most (83%)
R2 patients (n  30) were 18 years and are pre-
ented here. All patients received VP  TBI (1350
Gy in 11 fractions). GVHD prophylaxis consisted of
SA  prednisone, CSA  MTX  prednisone, or
SA MTX. At a median follow-up of 3.9 years, the
0-year EFS was 61%, and the 10-year OS was 62%.
von Bueltzingsloewen et al. [48] present the results
f a retrospective multicenter study (the number of
enters was not stated) of the Société Française de
reffe de Moelle of 21 pediatric (4 years at BMT)
atients with ALL who underwent transplantation
ith a matched related BMT between 1982 and 1992.
onditioning regimens were Bu-containing, non–
BI-based regimens that varied by center and date of
MT: Bu  Ara-C  Cy  VP  melphalan. Over-
apping criteria for BMT in CR1 were as follows: (1)
ge12 months at diagnosis; (2) non–T-cell ALL and
BC 100 000/L; (3) t(4;11); (4) t(9;22); (5) poor
esponse to initial therapy with corticosteroids ac-
ording to European Organization for the Research
nd Treatment of Cancer criteria; or (6) induction
ailure to ﬁrst-line therapy. At time of BMT, patients
ere in CR1 (n  15), CR2 or relapse (n  5), or
rimary induction failure (n 1). Sites of relapse were
solated BM (n  4) or IE (n  1). The median
uration of CR1 was 7 months. GVHD prophylaxis
onsisted of MTX  CSA (n  14), CSA alone (n 
), or MTX alone (n  2). The median time from last
R to BMT was 80 days. No patient died of TRM.
he 4-year DFS was 61.1% for all patients and 61.9%
or those who underwent transplantation in CR1. At a
edian follow-up of 47 months, OS was 68.6% and
2.2% for the entire group and those who underwent
ransplantation in CR1, respectively.
Buchanan et al. [49] performed a prospective mul-
icenter randomized trial of 297 pediatric (21 years
t diagnosis) patients with ALL from 1983 to 1986
ccording to Pediatric Oncology Group protocol
303 at 32 US centers. Patients received remission
nduction, consolidation, and maintenance chemo-
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8herapy and were in ﬁrst BM relapse within 6 months
f initial therapy. Patients were then randomized to
eceive or not receive repeated reinduction. Those
ith matched sibling donors could be treated with
llogeneic BMT instead of continued chemotherapy.
orty-two patients (16% of the Pediatric Oncology
roup 8303 study population) received marrow from
matched sibling (n  34), mismatched related donor
n  3), or ex vivo purged autologous marrow (n  5).
he median duration of CR1 was not indicated for the
MT group. Conditioning regimens and GVHD pro-
hylaxis varied among the 16 participating centers.
verall TRM in the BMT group was 41%; median
FS and OS were not stated. From the matched
ibling group, 15 died of TRM, 10 died of relapsed
LL, and 9 were alive and disease free 8 to 11 years
fter transplantation. Two mismatched related BMT
atients died of TRM, and the third is disease-free. Of
he BMT patients with autologous purged marrow, 4
elapsed, and one is disease free. OS and LFS were not
tated in the article.
Gordon et al. [50] performed a retrospective study
f 65 ALL (n  41), AML (n  22), or myelodysplas-
ic syndrome (n  2) pediatric (20 years at BMT)
atients who underwent related or unrelated BMT at
US centers between 1981 and 1994. Patients under-
ent transplantation for ALL in CR2 (n  27), CR3
n  6), or relapse (n  8). Good-risk patients were
onsidered ALL in CR2 (n  27). High-risk patients
ere considered ALL in CR3 (n  6) or relapse (n 
). The median duration of CR1 for good-risk (CR2)
atients was 24 months, and relapse sites were com-
ined BM (n 23), IE and BM (n 2), or IE (n 2).
ites of prior relapse and duration of CR1 were not
tated for the high-risk (CR3/relapse) group. The
onditioning regimen for all patients consisted of
ra-C and TBI (1200 cGy). Donors were matched
ibling (n  24; 1 syngeneic donor), class I antigen–
ismatched sibling or parent (n  2), or matched
nrelated (n  1). GVHD prophylaxis consisted of
othing or prednisone (n  23, as part of a GVHD
rophylaxis efﬁcacy study), MTX  prednisone (n 
6), CSA  MTX (n  8), or ATG  CSA  MTX
prednisone (n  8). TRM was 30% for ALL pa-
ients who underwent transplantation in CR2; TRM
as not stratiﬁed by disease (AML/myelodysplastic
yndrome versus ALL) in the high-risk group but was
2% for all high-risk patients. At a median follow-up
f 95 months, the 2-, 5-, and 10-year EFS for ALL
atients in CR2 was 59%, 59%, and 51%, respec-
ively.
Sanders et al. [51] performed a retrospective anal-
sis of 57 pediatric (18 years at BMT) patients with
LL who received a BMT in CR2 from HLA-iden-
ical siblings at a single US center between 1973 and
985. The duration of CR1 was1 year (n 11), 1 to
years (n  31), and 3 years (n  15); 35 patients s
44resented with extramedullary relapse (combined BM
ersus IE not speciﬁed). The conditioning regimen for
ll patients was intrathecal MTX  Cy  TBI (920-
575 cGy). GVHD prophylaxis was MTX (n  55) or
SA (n  2). Day 100 TRM was 25%. At a median
ollow-up of 4 years, the 5-year EFS was 40%.
Shah et al. [52] retrospectively evaluated 52 pedi-
tric (16 years at BMT) patients with ALL treated in
R1 (n  9), CR2 (n  34), or CR 3 (n  9) with
n HLA-matched related allogeneic BMT at a single
S center between 1989 and 2002. The conditioning
egimen consisted of Bu  Cy; GVHD prophylaxis
onsisted of MTX  CSA. CR1 duration was 18
onths in 26 patients and 18 months in 26 patients.
t a median follow-up of 8 years, the 3-year EFS was
0%, 36%, and 22% for CR1, CR2, and CR 3
atients, respectively (P value not stated). Neurocog-
itive function was assessed in 7 BMT patients before
MT and at 1 year after BMT and did not signiﬁ-
antly differ between the 2 time points. Seven normal
iblings were also tested for neurocognitive function,
nd their scores were compared with their affected
ibling’s pre-BMT scores. Normal siblings scored sig-
iﬁcantly higher than their affected siblings in overall
ognitive function (P  .02), verbal skills (P  .03),
erformance skills (P  .04), and receptive vocabulary
P  .01).
Moussalem et al. [53] retrospectively analyzed the
utcomes of 42 pediatric (15 years at BMT) patients
ith ALL who underwent allogeneic BMT in CR2 at
single French center between 1983 and 1993. Pa-
ients received marrow from HLA-identical siblings (n
38), unrelated phenotypically identical donors (n 
), an HLA-mismatched parent (n 1), or a syngeneic
onor (n  1). Immunophenotype was B lineage (n 
1), T lineage (n  6), or non B, non T (n  4);
atient karyotype was normal (n  10) or abnormal (n
16). Relapse sites were BM (n  23), combined BM
n  9), or IE (n  10); patients were stratiﬁed into
arly (18 months from CR1; n 12) or late (n 30)
elapse. The mean interval from diagnosis to BMT
as 35 months. The conditioning regimens consisted
f Ara-C  melphalan  TBI (n  20), Cy  TBI (n
10), Cy  Ara-C  VP  TBI (n  11), or Cy 
ra-C  Bu  melphalan (n  1). TBI doses varied
rom 1000 cGy as a single fraction to 1200 cGy in 6
ractions. GVHD prophylaxis was CSA MTX (n 
4), CSA alone (n  15), MTX alone (n  1), T-cell
epletion (n  1), or none (syngeneic BMT; n  1).
verall, TRM for the group was 31%. At a median
ollow up of 36 months, the 4-year EFS was 53%; the
nly factor that was signiﬁcantly related to EFS was
aryotype (normal versus abnormal, 40% versus 81%;
 .05).
Bordigoni et al. [54] conducted a retrospective
ulticenter study (the number of centers was not
tated) of 32 pediatric (17 years at BMT) patients
Table 7. Comparison of Patient Characteristics and Outcomes from Articles Included in the Unrelated Donor Allogeneic SCT Section
Reference
Quality and
Strength of
Evidence*
Patient
Populations
No. of
Patients
Upper Limit (Median)
Age at Time of
Transplantation (y)
Treatment-
Related
Mortality
Median
Follow-Up
(mo) LFS/EFS/DFS
Significance:
LFS/EFS/DFS† OS
Significance:
OS†
58 2 Single UK center Total 137 3-y LFS Not significant 3-y Not significant
Matched 85 17 (8) 17% 38 44.9% 48.7%
Mismatched 52 39.9% 41.7%
60 2 NMDP registry CR2
ALL patients
5-y LFS Not compared 5-y Not compared
363 19 (9) 42% 29 36% 38%
61 2 Single US center Total 88 3-y DFS 38% Not stated Not stated Not compared
ALL 43 17 (9) 28% Not stated CR1 or 2 47%
CR3 or Rlps 10%
62 2 Single US center 35 17.5 (8.8)‡ 36% 25.2 2-y DFS Not compared Not stated Not compared
30%
63 2 Single German center 16 24 (10)§ 35%§ 34 Not stated Not compared 2-y Not compared
56%
64 2 Single UK center
Ph patients
15 20 (8.3) Overall 20% Not stated
(minimum
7)
2-y DFS Not compared 2-y Not compared
Day 100 7% 37% 44%
LFS indicates leukemia-free survival; EFS, event-free survival; DFS, disease-free survival; OS, overall survival; NMDP, National Marrow Donor Program; CR2, second complete remission; ALL, acute
lymphoblastic leukemia; CR1, ﬁrst complete remission; CR3, third complete remission; Rlps, relapse.
*Quality and strength of evidence deﬁnitions are stated in Table 1.
†Not signiﬁcant: P  .05.
‡Includes 35 patients with ALL and 15 patients with AML.
§Includes 16 patients with ALL, 7 with AML, 6 with chronic myeloid leukemia, and 2 with juvenile myelomonocytic leukemia.
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8ith ALL in CR1 who received a BMT from an
LA-matched sibling donor between 1980 and 1987.
emission induction, consolidation, and maintenance
hemotherapy regimens varied; the median time from
R to BMT was 3 months. Criteria for BMT were a
igh WBC count (100 000/L; n 20), cytogenetic
bnormalities [t(8;14), t(9;22), t(4;11), t(7;12), and
p], 6 weeks to achieve CR, lymphoma-leukemia
yndrome, and/or adolescence. The conditioning reg-
men consisted of Cy TBI (1000-1600 cGy; n 28)
r other chemotherapy-based regimens (n  4).
here were 4 (12.5%) deaths due to TRM. At a
edian follow-up of 30 months, the 5-year LFS was
4.4%. The 5-year post-BMT relapse rate was 3.5%.
Coccia et al. [55] performed a prospective feasi-
ility trial of 20 pediatric (16 years at BMT) patients
ith ALL treated in CR2 (n  18) or CR3 (n  2)
ith an HLA-matched sibling allogeneic BMT at a
ingle US center between 1981 and 1986. The condi-
ioning regimen was Ara-C  TBI (1200 cGy in 6
ractions). GVHD prophylaxis consisted of MTX 
rednisolone (n  7), MTX (n  2), prednisolone (n
2), or nothing (n  9). At a median follow-up of 58
onths, the OS and EFS were 58% and 58%.
The following studies consisted of 70% pediat-
ic patients: Wingard et al. [56] presented the results
f 74 consecutive patients with ALL (50% were15
ears at the time of BMT) treated in CR1 (n  18),
R2 (n  36), CR3 (n  16), or CR4 (n  4) with an
LA-matched sibling BMT at a single US center
rom 1978 to 1988. The 18 CR1 patients were high
isk, deﬁned as having one of the following: age 18
ears, WBC 20 000/L at diagnosis, Ph, failure to
chieve CR1 in 6 weeks, or extramedullary disease.
wenty percent of all patients had extramedullary
isease at the time of BMT; sites of prior relapse were
ot stated. The median duration of CR1 in the CR2
atients was 13 months. All patients received Cy 
BI (1200 cGy in 4 fractions) as a conditioning reg-
men and low-dose Cy (n  29), low-dose Cy 
ethylprednisolone (n  8), CSA  methylpred-
isolone (n  12), or CSA alone (n  25) for GVHD
rophylaxis. At a median follow-up of 59 months, the
-year EFS was 42% in the CR1, 43% in the CR2,
5% in the CR3, and 0% in the CR4 groups (P value
ot stated).
Fleming et al. [57] reported the results of 16 HLA-
atched and 32 HLA-mismatched consecutive related
onor BMTs in patients with ALL conducted at a
ingle US center between 1987 and 1992. Fifty-six
ercent of the matched and 66% of the mismatched
MT patients were 15 years at the time of BMT.
emission states at the time of BMT were CR2 (n 
), CR3 (n  16), relapse 1 (n  7), relapse 2 (n  9),
elapse 3 (n  4), and relapse 4 (n  3). Sites of prior
elapse and duration of CR1 were not stated in the
rticle. All mismatched and 2 matched BMT patients P
46eceived ex vivo T-cell depletion with mAb and rabbit
omplement. Conditioning regimens varied; addi-
ional in vivo GVHD prophylaxis was given to all
atients as one of 5 regimens. At a median follow-up
f 46 months, LFS was not signiﬁcantly different
etween the HLA-matched versus -mismatched BMT
atients (median LFS, 49 versus 41 months; P  .48).
he LFS in the 6/6, 5/6, 4/6, and 3/6 HLA-matched
MT patients was 38%, 50%, 36%, and 30%, respec-
ively (P  .89).
NRELATED DONOR ALLOGENEIC STEM CELL
RANSPLANTATION
Table 7 summarizes the grading criteria, study pop-
lations, patient characteristics, and outcomes from pe-
iatric studies included in the URD allogeneic SCT
ection. Evidence in this section is taken from self-
escribed studies of pediatric populations, all of which
ncluded patients 21 years of age. Evidence is pre-
ented with the highest-quality studies ﬁrst; studies of
qual quality are presented in descending order with
he largest sample size ﬁrst.
Green et al. [58-59] retrospectively compared the
esults of HLA matching in 137 pediatric (18 years
t BMT) patients with ALL who underwent URD
MT at a single UK center from 1988 to 1999. Pa-
ients underwent transplantation in CR1 (n  24),
R2 (n  88), CR3 (n  18), CR4 (n  2), or relapse
n  5); relapse sites included isolated or combined
M (n  94) or IE (n  19). For patients in CR1, the
edian time from diagnosis to transplantation was
14 days. Eighty-ﬁve patients underwent transplanta-
ion with HLA-matched (at -A, -B, -DR, and -DQ)
M, and 52 transplants were mismatched. Ex vivo
-cell depletion (using Campath [Genzyme, Cam-
ridge, MA]) and CSA were used as GVHD prophy-
axis in 134 (98%) patients; in addition, 43 patients
lso received MTX because of HLA disparity. Con-
itioning regimens were either Campath Cy TBI
n 134) or Campath Cy Bu (n 3). Overall, 23
17%) patients died of TRM. At a median follow-up of
8 months, the 3-year LFS rates for the matched
ersus mismatched groups were 44.9% versus 39.9%,
nd the 3-year OS rates were 48.7% versus 41.7% (P
alue was not stated for each comparison). In a mul-
ivariate analysis of the 88 CR2 patients, the only
igniﬁcant factor predicting prolonged LFS was a
R1 duration 730 days (P  .007), although the
edian CR1 duration was not stated.
Bunin et al. [60] retrospectively examined the out-
ome of 363 pediatric (19 years at BMT) patients
ith ALL in CR2 who received an URD BMT at
ultiple centers (the number of centers was not
tated) facilitated by the National Marrow Donor
rogram between 1988 and 2000. The median CR1
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Cytotoxic Therapy with Hematopoietic SCT for ALL
Buration was 24 months; extramedullary disease was
resent in 52 patients (14.3%). Donors were mis-
atched at HLA-A, -B, or -DR in 24% of transplant
atients. Most patients (91%) received TBI-based
onditioning regimens; 40% received in vitro T-lym-
hocyte depletion by mAb  complement (58.3%),
lutriation (16.7%), lectin/sheep cell rosetting
12.5%), or other methods (12.5%). The 5-year TRM
as 42%; signiﬁcant factors for increased TRM by
ultivariate analysis were HLA mismatch (P 
0001), patient age 15 years (P  .0009), Karnofsky
erformance score 90 (P  .02), CR1 duration 12
onths (P  .02), and the time-dependent covariate
f grades III and IV acute GVHD (P  .0001). At a
edian follow-up of 29 months, the 5-year LFS and
S were 36% and 38%, respectively. Signiﬁcant mul-
ivariate predictors of longer LFS were HLA match (P
.0001), Karnofsky performance score 90 (P 
03), lower diagnostic WBC count (P  .002), age
15 years (P  .006), and CR1 duration 6 months
P  .002). T-cell depletion did not affect TRM or
FS. Acute GVHD grade III or IV occurred in 29%
f patients. Chronic GVHD occurred in 39% of pa-
ients and was signiﬁcantly more frequent for female
atients who received marrow from female donors (P
.0009).
Balduzzi et al. [61] performed a prospective phase
I study of URD BMT in 88 children (17 years at
MT) diagnosed with chronic myeloid leukemia (n 
6), ALL in CR1 or CR2 (n  15), more advanced
tage ALL (n  28), AML (n  13), or another
ematologic disease (n  16) at a single US center
etween 1985 and 1993. All patients received an iden-
ical conditioning regimen of Cy TBI and a GVHD
rophylaxis regimen of CSA MTX. URDs for ALL
atients were HLA identical (n  23) or minor mis-
atched (n  20). TRM occurred in 28% of patients
verall and was signiﬁcantly associated with HLA
atching and chronic GVHD (P  .04 and P  .02,
espectively). The 3-year DFS in ALL patients was
7% for patients in CR1 or CR2 and 10% in relapse
r CR3 patients. Disease-speciﬁc multivariate analyses
ere not presented.
Davies et al. [62] reported the results of 50 con-
ecutive pediatric (18 years at BMT) patients with
igh-risk acute leukemia (AML, n 15; ALL, n 35)
ho received an URD BMT between 1985 and 1994
t a single US center. Twenty-eight (80%) of the ALL
atients underwent transplantation in CR 2. Sites of
rior relapse and duration of CR1 were not stated.
verall, 60% of patients had HLA-identical donors,
ut this information was not stratiﬁed by diagnosis.
uration of CR1 and site(s) of relapse were not stated.
ll ALL patients received TBI-based conditioning
egimens. GVHD prophylaxis consisted of CSA 
TX in 78% of patients; T-cell depletion and otherrophylaxis combinations were used in the remaining p
B&MT2%. The day 100 TRM was 36%. At a median
ollow-up of 25 months, the 1- and 2-year DFS for
LL patients was 37% and 30%, respectively, and was
ot signiﬁcantly different between HLA-matched ver-
us mismatched donors.
Lang et al. [63] performed a prospective feasibility
rial of CD34-selected PBSCT from URDs in 31
ediatric (1 patient was 18 years) patients with ALL
n  16), AML (n  7), chronic myeloid leukemia (n
6), or juvenile myelomonocytic leukemia (n  2) at
single German center from 1997 to 2000. Of the 31
atients, 15 were HLA matched, 13 were 1-antigen
ismatched, and 3 were 2-antigen mismatched. The
LL patients were in CR 2 (n  14) or relapse 1
n  2) at the time of PBSCT. The duration of CR1
nd sites of prior relapse were not stated. Condition-
ng regimens for patients with ALL were Cy or thio-
epa with ATG  TBI (1200 cGy in 6 fractions; n 
4) and Bu  Cy  VP  ATG (n  2). No patients
eceived posttransplantation immunosuppression. At a
edian follow-up of 2.8 years, the 2-year OS was 56%
or all patients with ALL and 63% for patients with
LL in remission.
Marks et al. [64] retrospectively examined 15 pe-
iatric (19 years at diagnosis) patients with Ph
LL who received T cell–depleted URD BMT at a
ingle UK center between 1990 and 1996. Patients
ere in CR1 (n  9), CR2 (n  3), CR3 (n  1), CR4
n  1), or relapse (n  1). Sites of relapse and
uration of CR1 were not stated in the article. All
atients received Campath  Cy  TBI as condition-
ng; T-cell depletion was performed by using either
ampath (n  12) or CD34 selection (n  3). In
ddition, CSA MTX was given for GVHD prophy-
axis. Eleven donor/recipient pairs were identical at
LA-A, -B, -DRB1, and -DQB1, and 4 were mis-
atched at 1 or 2 loci. Overall, 3 (20%) patients died
f TRM; 100-day TRM was 7%. Two-year DFS and
S are 37% and 44%, respectively. None of the
ismatched donor patients survived versus 64% of
atients with matched donors (P  .05).
ELATED VERSUS UNRELATED DONOR ALLOGENEIC
TEM CELL TRANSPLANTATION
Table 8 summarizes the grading criteria, study
opulations, patient characteristics, and outcomes
rom pediatric studies included in the related versus
RD allogeneic SCT section. Evidence in this section
s taken from self-described studies of pediatric pop-
lations, all of which included patients 21 years of
ge. Evidence is presented with the highest-quality
tudies ﬁrst; studies of equal quality are presented in
escending order with the largest sample size ﬁrst.
Dini et al. [65] analyzed the outcomes of 167
ediatric (17 years at BMT) patients with ALL who
847
Table 8. Comparison of Patient Characteristics and Outcomes from Articles Included in the Related versus Unrelated Donor Allogeneic Transplantation Section
Reference
Quality and
Strength of
Evidence*
Patient
Populations
No. of
Patients
Upper Limit
(Median) Age
at Time of
Transplantation (y)
Treatment-
Related
Mortality
Median
Follow-Up
(mo) LFS/EFS/DFS
Significance:
LFS/EFS/DFS OS
Significance:
OS
65 2 AIEOP centers Total 167 Overall 3-y DFS Not compared 3-y Not compared
URD 60 16 (7.6) 47% 65 31.6% 31.6%
Alt Donor 40† 30% 25.4% 30.8%
Chemo 67 7% Not stated Not stated
66 2 Single Danish center Total 67‡ 3-y 3-y LFS P < .01§ Not stated Not compared
1985–1989 Related 32 19 (8) 6% 41 72%
1990–1996 Related 19 19 (8) 21% 28%
1990–1996 URD 16 19 (12) 25% 67%
67 2 Population-based
Nordic registry
Total 43 Overall Not stated Overall EFS Not significant Not stated Not compared
Related 14 15 (not stated) 14% 45%
URD 29 17% 65%
68 2 Nordic ALL
protocols
Total 65‡ Overall 5-y EFS Not significant Not stated Not compared
Related 37 20 (not stated) 19% 54 39%
URD 28 11% 54%
LFS indicates leukemia-free survival; EFS, event-free survival; DFS, disease-free survival; OS, overall survival; AIEOP, Associazione Italian di Ematologica ed Oncologica Pediatrica; URD, unrelated
donor; Alt Donor, alternative donor; Chemo, chemotherapy; ALL, acute lymphoblastic leukemia.
*Quality and strength of evidence deﬁnitions are listed in Table 1.
†Includes 17 autologous, 16 haploidentical relative, 5 unrelated cord blood, and 2 related cord blood.
‡Fourteen patients in reference 66 are also included in reference 68.
§The P value comparing the related BMT 1985–1989 versus 1990–1996 groups; P  .002 comparing related BMT 1990–1996 versus URD 1990–1996.
P  0.05.
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Cytotoxic Therapy with Hematopoietic SCT for ALL
Bad a URD search performed through the Italian
one Marrow Donor Registry from 1989 to 1998. All
atients had experienced a BM relapse before search
nitiation and had achieved at least a CR2 before SCT.
he duration of CR1 was 30 months in 71% of
atients. A matched URD was found for 70 (42%)
atients at a median of 5.4 months after search initi-
tion, of whom 46 underwent a URD SCT in CR2, 14
ad a URD SCT in CR 2, 1 had a haploidentical
elated SCT, and 9 were treated with chemotherapy at
ultiple centers (the number of centers was not
tated). A URD was not found for 97 (58%) patients,
f whom 17 underwent alternative donor SCT in CR2
9 autologous, 4 unrelated cord blood transplant, 2
elated cord blood transplant, and 2 haploidentical
arent), 22 underwent alternative donor SCT in CR3
8 autologous, 13 haploidentical relative, and 1 unre-
ated cord blood transplant), and 58 were treated with
hemotherapy. At a median follow-up of 5.4 years, the
-year DFS in all patients was 15.1%. The 3-year
FS was signiﬁcantly better in the patients whose
R1 duration was 30 months compared with a du-
ation of 30 months, regardless of the treatment
eceived (34.7% versus 6.4%; P  .001). The 3-year
FS for the URD SCT group was 31.6% versus
5.4% for the alternative donor SCT group (P value
ot stated).
Lausen et al. [66] present the results of a popula-
ion-based single-institution study of all Danish pedi-
tric (20 years at BMT) patients with ALL (n  67)
ho underwent allogeneic BMT between 1985 and
996. Patients were stratiﬁed into 3 groups: patients
ith HLA-matched sibling donors who underwent
ransplantation between 1985 and 1989 (group 1; n 
2), family donors between 1990 and 1996 (group 2; n
19, including 11 HLA-matched siblings, 5 HLA-
atched other family members, and 3 HLA-mis-
atched siblings), and URDs between 1990 and 1996
group 3; n  16, including 12 HLA-matched and 4
LA-mismatched donors). Sixty-seven percent of pa-
ients underwent transplantation in CR2, 16% in
R1, and 16% in CR 2, with no signiﬁcant differ-
nces between the donor groups. Neither sites of
elapse nor IE disease was speciﬁed. Median CR1
uration was 28 months for each donor group. The
edian time from diagnosis to BMT ranged from 30
o 34 months and was not signiﬁcantly different be-
ween the donor groups. Conditioning regimens con-
isted of Cy  TBI (1200 cGy; 87%) or Bu  Cy
13%); ATG was given to patients receiving marrow
rom donors other than HLA-identical siblings.
VHD prophylaxis consisted of CSA  MTX. The
-year TRM for the 3 groups was 6%, 21%, and 25%,
espectively. At a median follow-up of 41 months, the
-year LFS of all family donors (groups 1 and 2) and
RD donors (group 3) was 56% and 67%, respec-ively; LFS for HLA-identical sibling donors versus 5
B&MTther family members was 55% and 58%, respec-
ively. Comparing family versus URD donors who
nderwent transplantation during the same time pe-
iod (groups 2 versus 3), LFS was signiﬁcantly higher
or URD transplants (67% versus 28%; P  .002).
FS was signiﬁcantly worse for patients receiving
oth CSA and MTX versus patients receiving either as
single agent for GVHD prophylaxis (P  .0005).
Saarinen-Pihkala et al. [67] analyzed a population-
ased cohort of all consecutive pediatric (16 years at
iagnosis) patients diagnosed with ALL in 5 Nordic
ountries from 1992 to 2000. A total of 1456 patients
ere registered in the database, 426 (29%) of whom
ere deﬁned as high or very high risk. Of these, 43
atients were treated with a related (n  14) or unre-
ated (n  29) BMT in CR1 if they had one of the
ollowing high-risk features: t(9;22), n  19; t(4;11), n
1; WBC 200 000/L  other factors, n  11;
BC 100 000/L  other factors, n  5; or poor
esponse, n  7. Median follow-up, conditioning reg-
mens, and GVHD prophylaxis regimens were not
tated. There was no difference in TRM between the
elated and unrelated BMT groups (14% versus 17%;
not stated). There was no signiﬁcant difference in
he overall EFS between the 2 groups (45% versus
5%; P  .20).
Saarinen-Pihkala et al. [68] performed a popula-
ion-based study of all 65 pediatric (16 years at
iagnosis) patients with ALL who underwent BMT in
R2 from either matched sibling donors (n  37) or
RDs (n  28) between 1990 and 1997 at 7 Nordic
enters. All patients were treated with common Nor-
ic ALL protocols. Relapse for sibling and URD
roups occurred as isolated BM (n  26 and 16),
ombined BM (n  6 and 7), or IE (n  5 and 5). The
edian CR1 duration was not stated; however, 41%
f patients with matched sibling donors versus 18% of
atients with URD relapsed 6 months after com-
leting therapy (P  .05). Conditioning regimens
ere TBI based (n  43), Bu  Cy  ATG (n  17),
r other (n  4) [editorial note: numbers for condi-
ioning regimens do not add up but are given as stated
n the article]. GVHD prophylaxis in the matched
ibling group consisted of CSA in all patients; MTX
as also given in 67% of patients. GVHD prophylaxis
n the URD group consisted of CSAMTX; 64% also
eceived ATG, and 11% received T-cell depletion.
RM was 11% and 19% for the URD and sibling
roups, respectively. The incidence of grade II to IV
cute GVHD was signiﬁcantly higher in the URD
roup (64% versus 38%; P  .05); chronic GVHD
as also signiﬁcantly more common in the URD
roup (58% versus 26%; P  .05). At a median fol-
ow-up of 4.5 years, the EFS and OS for the URD
ersus sibling group were not signiﬁcantly different:
4% versus 39% and 54% versus 42%, respectively.
849
Table 9. Comparison of Patient Characteristics and Outcomes from Articles Included in the Comparison of Conditioning Regimens in Allogeneic Transplantation Section
Reference
Quality and
Strength of
Evidence*
Patient
Populations
No. of
Patients
Upper Limit
(Median) Age at
Transplantation (y)
Treatment-
Related
Mortality
Median
Follow-up
(mo) LFS/EFS/DFS
Significance:
LFS/EFS/DFS‡ OS
Significance:
OS‡
69 1 Multicenter US RCT Total 43 Overall 3-y EFS P  .03 3-y P  .09
Bu/VP/Cy 21 20 (8) 24% 43.3 29% 47%
TBI/VP/Cy 22 9% 58% 67%
70 2 IBMTR database, 144
institutions
Total 627 3-y 3-y LFS P  .005 3-y P  .003
Cy  TBI 451 20 (12.9) 15% 37 50% 55%
Bu  Cy 176 20 (11.3) 23% 35% 40%
71 2 Single US center Total 123 Day 100 5-y DFS Not significant Overall Not compared
Cy  TBI 80 61 (14) 17%† 94 29% 34%
Ara-C  TBI 15 63% 27%
Cy  hfTBI 28 17%† 32%
72 2 Single Australian center Total 51 Day 100 EFS Not significant OS Not significant
Bu/Cy/Mel 26 Not stated 31% 58 27% 34%
TBI  other 25 (not stated) 8% 117 36% 40%
<70% Pediatric
patients
73§ 2 2 Spanish centers Total 156 18-mo 6-y EFS P  .01 Not stated Not compared
Bu  other 42 49 (15) 22% 48 22%
TBI  other 114 59 (18) 17% 72 43%
LFS indicates leukemia-free survival; EFS, event-free survival; DFS, disease-free survival; OS, overall survival; RCT, randomized controlled trial; Bu, busulfan; VP, etoposide; Cy, cyclophosphamide;
TBI, total body irradiation; IBMTR, International Bone Marrow Transplant Registry; Ara-C, cytosine arabinoside; hf, hyperfractionated; Mel, melphalan.
*Quality and strength of evidence deﬁnitions are listed in Table 1.
‡Not signiﬁcant: P  .10.
†Both the Cy  TBI and CY  hfTBI groups combined had a day 100 TRM of 17%, which was signiﬁcantly lower than the Ara-C  TBI group (P  .0001).
§70% of patients met inclusion criteria.
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Cytotoxic Therapy with Hematopoietic SCT for ALL
Bhere was no correction for time-to-transplantation
ias.
OMPARISON OF CONDITIONING REGIMENS IN
LLOGENEIC STEM CELL TRANSPLANTATION
ATIENTS
Table 9 summarizes the grading criteria, study
opulations, patient characteristics, and outcomes
rom pediatric studies included in the comparison of
onditioning regimens in allogeneic SCT section. Ev-
dence in this section is taken from self-described
tudies of pediatric populations, all of which included
atients 21 years of age. Evidence is presented in
escending order with the largest sample size ﬁrst.
Bunin et al. [69] performed a prospective random-
zed trial of 43 pediatric (21 years at BMT) patients
ith ALL treated with an allogeneic BMT at 11 cen-
ers of the Pediatric Blood and Marrow Transplant
onsortium from 1997 to 2000. Patients were ran-
omized to receive Bu  VP  Cy (n  21) or TBI
1200 cGy in 6 fractions)  VP  Cy (n  22) as a
onditioning regimen. Randomization was stratiﬁed
igure 8. Kaplan-Meier survival estimates by conditioning and
onor. MRD indicates matched related donor. Reprinted with per-
ission.69
igure 9. Actuarial probability of leukemia-free survival after HLA-
dentical sibling bone marrow transplantation for childhood ALL,
y pretransplantation conditioning regimen. Reprinted with per-dission.70
B&MTy CR1 duration, remission status at BMT, and prior
ranial irradiation. Patients in the Bu  VP  Cy
roup had a matched related donor (n  11) or
atched URD (n  10). Patients in the TBI  VP 
y group had a matched related donor (n  10) or
atched URD (n  12). TRM was higher in the
u-treated group (24% versus 9%), but the P value
as not stated for the comparison. At a median fol-
ow-up of 43.3 months, the 3-year EFS was signiﬁ-
antly better in the TBI  VP  Cy group (58%
ersus 29%; P  .03; Figure 8). There was no signif-
cant difference in the 3-year OS for the 2 groups
67% for the TBI group versus 47% for the Bu group;
 .09). There was no difference in EFS between the
atients who received a BMT from a related versus
RD (46% versus 40%; P  .30).
Davies et al. [70] compared the outcomes of 2
onditioning regimens in a retrospective cohort study
f the International Bone Marrow Transplant Regis-
ry. Pediatric (20 years at BMT) patients from 144
nstitutions with ALL who underwent transplantation
etween 1988 and 1995 and who received Cy  TBI
total, n  451; fractionated 1200 cGy, n  253;
ractionated 1200 cGy, n  117; unfractionated
1000 cGy, n 72; unfractionated1000 cGy, n 9)
r BuCy (n 176) as a conditioning regimen for an
LA-identical sibling BMT were included. For the
y  TBI group, disease status at BMT was CR1 (n
134), CR2 (n 194), CR3 (n 51), or not in CR
n  72), with a median CR1 duration (for patients
ho underwent transplantation beyond CR1) of 18.98
onths and a median interval between CR1 and BMT
f 3.95 months (for patients who underwent trans-
lantation in CR1). For the Bu  Cy group, disease
tatus at BMT was CR1 (n  51), CR2 (n  73), CR
3 (n  27), or not in CR (n  25), with a median
R1 duration of 23.16 months (for patients who un-
igure 10. Comparison of 3 conditioning regimens used for allo-
eneic BMT for ALL: disease-free survival. Follow-up after BMT
iffers because the cyclophosphamide/TBI (single-dose and frac-
ionated) regimens were used from 1979 to 1983 (thin line), TBI/
raC was used from 1984 to 1987 (dashed line), and hyperfraction-
ted TBI/cyclophosphamide was used from 1987 to 1991 (bold
ine). Reprinted with permission.71erwent transplantation beyond CR1), and the me-
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T. Hahn et al.
8ian interval between CR1 and BMT was 4.96 months
for patients who underwent transplantation in CR1).
ites of relapse (BM versus extramedullary) were not
igniﬁcantly different between the 2 groups (P  .30);
owever, the rates of relapse sites were not speciﬁcally
tated. The 3-year cumulative incidence of TRM was
5% versus 23% for the Cy  TBI and Bu  Cy
ohorts, respectively (P  .02). At a median follow-up
f 37 months, the 3-year LFS rates were 50% and
5% (P  .005; Figure 9), and the 3-year OS rates
ere 55% versus 40% for the Cy  TBI versus Bu 
y groups, respectively (P  .003). In the univariate
nd multivariate analyses, the OS and LFS of the Cy
TBI group were signiﬁcantly greater, the risk of
RM was lower, and the risk of relapse was not
igniﬁcantly different from those of the Bu  Cy
roup. Other factors (in addition to conditioning reg-
men) that were associated with lower survival rates by
ultivariate analysis were BMT while not in CR,
hort duration of CR1, presence of t(4;11) transloca-
ion, and use of T-cell depletion or combined MTX
SA versus CSA or MTX alone for GVHD prophy-
axis.
Weisdorf et al. [71] retrospectively compared the
ong-term outcomes of 4 conditioning regimens used
or HLA-matched sibling allogeneic BMTs for 123
atients with ALL (75% were 20 years at BMT)
reated at a single US center from 1979 to 1991.
ighty-ﬁve percent of patients underwent transplan-
ation in CR 2. The duration of CR1 was 18
onths in 35% of all patients. Thirty-seven (30%)
atients had extramedullary disease at any site. Con-
itioning regimens included Cy  TBI  VM-26
ra-C (750 cGy in a single dose; 1979-1981; n  35),
y  fractionated TBI (1320 cGy in 8 fractions;
982-1984; n  45), Ara-C  TBI (850 cGy in a
ingle dose; 1984-1987; n  15), and Cy  hyperfrac-
ionated TBI (1320 cGy in 11 fractions; 1987-1991; n
28). The ﬁrst 2 groups were combined for the
nalysis. At a median follow-up of 7.8 years, there was
o signiﬁcant difference in the 5-year DFS for these
roups (Cy  TBI, 29%; Ara-C  TBI, 27%; Cy 
yperfractionated TBI, 32%; P .60; Figure 10). Day
00 TRM was signiﬁcantly higher for the Ara-C 
BI group versus the Cy  TBI groups (63% versus
7%; P  .0001).
Carpenter et al. [72] performed a study comparing
hemotherapy versus TBI-based conditioning regi-
ens in pediatric (upper age limit not deﬁned) pa-
ients with ALL treated with an allogeneic BMT (do-
or relation not deﬁned) at a single Australian center.
atients in the chemotherapy conditioning regimen
roup (n  26) were prospectively enrolled between
988 and 1993 and received Bu  Cy  melphalan.
atients in the TBI-based conditioning regimen
roup were a historical control group (n  25) treated
etween 1979 and 1988 and received Cy  TBI (n  g
522; single-fraction 1000 cGy, n  2; 1200-1320 cGy
n 6 fractions, n  20); 3 patients in the Cy  TBI
roup also received Ara-C or Bu  Cy (n  3). Day
00 TRM for the chemotherapy-based conditioning
egimen group was 31%; at a median follow-up of 58
onths, EFS and OS were 27% and 34%, respec-
ively. Day 100 TRM for the TBI-based conditioning
egimen group was 8%; at a median follow-up of 117
onths, EFS and OS were 36% and 40%, respec-
ively. Differences in EFS, OS, and relapse rates were
ot statistically signiﬁcant between the groups. The
nly signiﬁcant difference between the 2 groups was
eath due to GVHD, which was higher in the che-
otherapy group (P  .05).
The following study consists of 70% pediatric
atients: Granados et al. [73] retrospectively com-
ared the outcomes of TBI-based (n  114) versus
u-based (n  42) conditioning regimens in 156 con-
ecutive patients with ALL (50% were 18 years
ld at BMT) treated with an autologous (n  66) or
atched sibling allogeneic (n 90) BMT at 2 Spanish
enters from 1983 to 1997. Most patients received Cy
n combination with Bu or TBI (1200 cGy in 4 [n 
9] or 6 [n 85] fractions) for conditioning. Forty-six
ercent underwent transplantation in CR1, 33% in
R2, and 22% in more advanced disease. Sites of
rior relapse were not stated. The median duration of
R1 was 7.5 versus 5.3 months for the TBI- versus
u-based groups (P  .15). Five of the autologous
MT patients received grafts purged with mAbs.
VHD prophylaxis consisted of CSA  MTX in
ost allogeneic BMTs (the exact number was not
tated). At a median follow-up of 4 years in the
u-based group and 6 years in the TBI-based group,
he 6-year EFS was signiﬁcantly different (22% versus
3%; P .01). Signiﬁcant risk factors for shorter EFS
y multivariate analysis were Bu-based regimens (P 
01), advanced disease (P  .0001), absence of chronic
VHD (P .008), shorter duration of CR1 (P .02),
nd development of veno-occlusive disease (P .006).
UTOLOGOUS VERSUS ALLOGENEIC STEM CELL
RANSPLANTATION
Table 10 summarizes the grading criteria, study
opulations, patient characteristics, and outcomes
rom pediatric studies included in the autologous ver-
us allogeneic SCT section. Evidence in this section is
aken from self-described studies of pediatric popula-
ions, all of which included patients 21 years of age.
vidence is presented with the highest-quality studies
rst; studies of equal quality are presented in descend-
ng order with the largest sample size ﬁrst.
Weisdorf et al. [74] compared the outcomes of 214
onsecutive patients with ALL who received autolo-
ous BMT from 1987 to 1993 at 2 US centers with
Table 10. Comparison of Patient Characteristics and Outcomes from Articles Included in the Autologous versus Allogeneic SCT Section
Reference
Quality and
Strength of
Evidence* Patient Populations
No. of
Patients
Upper Limit
(Median) Age
at Time of
Transplantation
(y)
Treatment-
Related
Mortality
Median
Follow-up
(mo) LFS/EFS/DFS
Significance:
LFS/EFS/DFS
74 2 2 US centers and
NMDP
Total 551 Overall DFS in CR1/CR2 P  .03/.02
Auto 214 Not stated† 15.9% 34 42%/20%
URD 337 Not stated† 49.9% 25 32%/42%
75 2 Italian AIEOP
multicenter
study‡
Total 75 Day 180 3-y EFS Not stated
Auto 29 18 (8.5) 7% 34 39%
Allo 46 15.8% 64%
76 2 Single US center§ Total 74 At diagnosis Day 100 3-y EFS Not stated
Auto 57 15 (4.2) 7% 58 47%
Allo 17 18 (4.1) 18% 55 53%
77 2 MRC UKALL R1
protocol
Total 256 (CR 243) At diagnosis 5-y EFS Not stated
Chemo 123 15 (not stated) Overall 47%
Auto 15 12% 59 47%
Related 63 45%
URD 42 53%
78 2 Italian AIEOP
multicenter
study;
Total 48 No. <15 y 55-mo DFS P  .0114
Auto 30 27 10% 12 12.7%
Allo 18 12 11% 23 43.3%
ALL R-87 protocol
82 2 EBMT (Auto) Total 354 Overall 2-y LFS Not stated
IMUST (URD) Auto 236 56 (16) 17% 9 32%
URD 118 54 (14) 42% 23 39%
83 2 Single US center Total 68 1-y Not stated 3-y DFS P  .58
Auto 52 45 (not stated) 13% 15%
Allo 16 45 (not stated) 44% 31%
84 2 Single US center Total 32 Not stated Not stated Not compared
Auto 25 43 (18) 36%
Allo 7 17 (13) 43%
LFS indicates leukemia-free survival; EFS, event-free survival; DFS, disease-free survival; OS, overall survival; NMDP, National Marrow Donor Program; Auto, autologous; URD, unrelated donor;
AIEOP, Associazione Italiana di Ematologia ed Oncologia Pediatrica; Allo, allogeneic; MRC, Medical Research Council; ALL, acute lymphoblastic leukemia; Chemo, standard chemotherapy
comparison group; EBMT, European Group for Blood and Marrow Transplant; IMUST, International Marrow Unrelated Search and Transplant.
*Quality and strength of evidence deﬁnitions are listed in Table 1.
†A total of 75% of the autologous BMT group were 18 years; 64% of the unrelated allogeneic BMT group were 18 years.
‡This study overlaps with reference 13.
§This study overlaps with reference 28.
Less than 70% of patients were pediatric.
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8hose of 337 unrelated allogeneic BMT patients
reated during the same period and reported to the
ational Marrow Donor Program. Seventy-ﬁve per-
ent of the autologous and 64% of the unrelated BMT
roup were 18 years at the time of BMT. Remission
tatus for autologous BMT patients were 23.8% CR1,
5.8% CR2, 24.8% CR 3, and 5.6% relapsed/pri-
ary induction failure. Remission status for unrelated
llogeneic BMT patients were 15.6% CR1, 31.7%
R2, 27.8% CR 3, and 24.9% relapsed/primary
nduction failure. Patient age, remission status at
MT, year of BMT, and conditioning regimen were
igniﬁcantly different between the 2 groups. National
arrow Donor Program patients did not have infor-
ation regarding 3 prognostic factors: diagnostic
BC, duration of CR1, and site(s) of relapse. At a
edian follow-up of 34 months in the autologous and
5 months in the unrelated allogeneic BMT groups,
he DFS, relapse, and TRM rates signiﬁcantly differed
y remission status, age, and sex. Multivariate analysis
emonstrated a signiﬁcantly better DFS with unre-
ated allogeneic BMT in female patients18 years old
34.1% versus 17.5%; P  .04). There was no signif-
cant difference between unrelated allogeneic and au-
ologous BMT for adults (18 years) or male children
18 years).
Uderzo et al. [75] investigated the efﬁcacy of a
ovel conditioning regimen in 75 consecutive pediat-
ic (18 years at diagnosis) patients with ALL who
eceived allogeneic or autologous BMT in CR2 at 7
IEOP centers between 1986 and 1993. There is
verlap with Uderzo et al. [13]. All patients received
he same ﬁrst-line therapy; second-line treatment was
ccording to AIEOP protocol or a BFM-like multiple-
rug relapse protocol. Patients with HLA-identical
HLA-A, -B, and -DR) sibling donors (n  46) un-
erwent allogeneic BMT, and the remainder under-
ent autologous BMT (n  29). Relapse sites for the
llogeneic BMT group were isolated or combined BM
elapse (n  33) or IE (n  13). Relapse sites for the
utologous BMT group were isolated or combined
M relapse (n  23) or IE (n  6). The median CR1
uration was 26 and 25 months for allogeneic and
utologous BMT patients, respectively. All patients
eceived an identical conditioning regimen of high-
ose vincristine  Cy  TBI (1200 cGy in 6 frac-
ions). Twenty-three of 29 autologous BMT patients
eceived in vitro purged marrow with vincristine 
rednisolone (n  13), mafosfamide (n  8), or mAbs
n  2). GVHD prophylaxis consisted of CSA for
llogeneic BMT patients. Day 180 TRM occurred
n 15.8% and 7% of patients in the allogeneic and
utologous BMT groups, respectively. Grade III or IV
cute GVHD occurred in 11.9% of the allogeneic
MT group; chronic GVHD occurred in 20.5%. At a
edian follow-up of 34 months, the 3-year EFS was
4% for the allogeneic BMT group versus 39% for d
54he autologous group (P  .09). In patients with IE
elapse, the 3-year EFS was 76.9% and 83.3% for the
llogeneic and autologous groups, respectively.
Parsons et al. [76] performed a retrospective co-
ort study of 74 relapsed pediatric (18 years at
MT) patients with B-precursor ALL in CR 2 who
eceived allogeneic (n  17) or autologous (n  57)
MT at a single US center between 1986 and 1992.
here is overlap with Billet et al. [28]. All patients in
oth groups met the same eligibility criteria: age 18
ears, in CR 2 after at least one BM relapse, B-
ineage ALL, and the absence of high-risk features [ie,
nduction failure, t(9:22), or T-cell disease]. Autolo-
ous marrow was purged in vitro with antibody and
omplement. Both groups received TBI-based condi-
ioning regimens (TBI was administered in 175-cGy
oses for 8 fractions totaling 1400 cGy). GVHD pro-
hylaxis was MTX alone (n  13) or MTX  CSA (n
4) for the allogeneic group. The median CR1 du-
ation for the autologous and allogeneic groups were
6.0 and 33.4 months, respectively. Disease status for
he autologous and allogeneic groups was CR2 (n 
4 and 14, respectively), CR3 (n  20 and 3, respec-
ively), and CR 3 (n  3 and 0, respectively). Day
00 TRM was 7% for autologous and 18% for allo-
eneic transplantations. At median follow-ups of 4.8
nd 4.6 years, EFS at 3 years was 47% versus 53% for
he autologous versus allogeneic groups, respectively
P  .77).
Lawson et al. [77] presented the results of 256
ediatric (15 years at diagnosis) patients with re-
apsed ALL enrolled in the multicenter MRC
KALL R1 protocol between 1991 and 1995 (the
umber of centers was not stated). All patients re-
eived standardized reinduction and consolidation
egimens. Of the 243 patients who achieved CR2, 120
roceeded to autologous (n 15), related (n 63), or
nrelated (n  42) BMT. For the transplantation
roup, CR1 duration was 2 years (n  25), 2 to 2.5
ears (n  42), or 2.5 years (n  53); sites of relapse
ere BM (n  96), isolated CNS (n  14), or other (n
10). GVHD prophylaxis and conditioning regimens
ere not speciﬁed. Fourteen (12%) transplant patients
7 related and 7 unrelated) died of TRM. The 5-year
FS rates for autologous, related, and URD BMT
ere 47%, 45%, and 52%, respectively.
Giona et al. [78-81] reported the prospectively
esigned Italian multicenter ALL R-87 study of 147
onsecutive pediatric (81% of BMT patients were
15 years at diagnosis) patients with relapsed or re-
ractory ALL at 13 AIEOP centers between 1987 and
992. Patients were treated with a reinduction and
onsolidation phase and, if a CR was achieved (n 
7), were eligible to receive an autologous (n  30) or
llogeneic (n 18) BMT. Thirty patients had an early
elapse, and 19 withdrew from the study. The median
uration of CR1 and sites of relapse were stated for
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Cytotoxic Therapy with Hematopoietic SCT for ALL
Bhe 147 enrolled patients, but not for the 48 BMT
atients. Thirty-ﬁve patients (24 autologous and 11
llogeneic) received Bu  Cy, 9 (3 autologous and 6
llogeneic) received Cy  TBI, and 4 patients re-
eived other regimens as conditioning. Marrow was
urged with mafosfamide in 20 of 30 autologous
ransplants. At a median follow-up of 12 months in the
utologous group and 23 months in the allogeneic
roup, the DFS was signiﬁcantly improved in the
llogeneic group (43.3% versus 12.7%; P  .0114).
The following studies consist of 70% pediatric
atients: Ringden et al. [82] conducted a matched-pair
nalysis that compared 118 matched unrelated alloge-
eic BMT patients treated for ALL and registered in
he International Marrow Unrelated Search and
ransplant study from 1987 to 1994 with 236 autol-
gous BMT ALL patients reported to the European
roup of Blood and Marrow Transplant registry from
he same time period. Half of the autologous and
nrelated BMT groups were 16 and 14 years at
he time of BMT, respectively. Cases were matched
:1 with controls on disease status at the time of
ransplantation (CR1, CR2, or CR3), age (20, 20-40,
r 40 years), and year of BMT. Sites of relapse and
uration of CR1 were not stated. Unrelated BMT
atients were excluded from the analysis if they did
ot have a matched autologous control (n  88), were
second BMT (n  31), had missing values (n  23),
r had secondary (n  11) or undifferentiated (n  7)
eukemia. TRM was signiﬁcantly higher in the unre-
ated allogeneic BMT group (42% versus 17%; P 
0001), whereas the relapse rate was signiﬁcantly
igher in the autologous BMT group (61% versus
2%; P  .0001). At a median follow-up of 9 and 23
onths in the autologous and unrelated BMT groups,
espectively, the 2-year LFS (32% versus 39%; P 
45) and OS (43% versus 39%; P  .15) were not
igniﬁcantly different.
Woods et al. [83] performed a prospective trial of
single conditioning regimen for both autologous and
llogeneic BMT in patients with ALL (65% were16
ears at BMT) at a single US center from 1985 to
987. The conditioning regimen consisted of Ara-C
BI (850 cGy in a single fraction). Allogeneic BMT
atients received MTX  ATG  prednisone as
VHD prophylaxis. Autologous BMT patients re-
eived marrow purged with mAbs  4-hydroperoxy-
yclophosphamide; BM was harvested in the same
emission as the transplantation. Median follow-up
as not stated. The 3-year DFS was similar between
he autologous versus allogeneic groups (15% versus
1%; P  .58). There was also no signiﬁcant differ-
nce in the 3-year OS (16% versus 38%; P  .74).
Bostrom et al. [84] reported the results of 25
atients with ALL (50% were 18 years at BMT)
ith advanced disease who received a purged autolo-
ous BMT and 7 pediatric ALL patients (100% were t
B&MT18 years at BMT) who received a related allogeneic
MT from 1987 to 1988 at a single US center. The
emission status of the purged autologous BMT pa-
ients were CR2 (n  6), CR 3 (n  6), relapse 1 (n
3), relapse 2 (n  9), or primary induction failure
n  1). The remission status of the related allogeneic
MT patients were relapse 1 (n  3) and relapse 2
n  4). Purging methods included 4-hydroperoxycy-
lophosphamide and either anti-B (anti-CD9, -CD10,
nd -CD24) or anti-T (anti-CD5 and -CD7) mAbs.
ll patients received VP  Cy  TBI (850 cGy in a
ingle dose) as a conditioning regimen; GVHD pro-
hylaxis consisted of MTX  ATG  prednisone.
ine (36%) autologous and 3 (43%) allogeneic BMT
atients died of TRM within 7 months after BMT. All
emaining patients who received a purged autologous
MT relapsed by a median of 4.2 months after BMT.
ne (14%) patient who received an allogeneic BMT
urvived disease free for 15 months after BMT.
UTURE DIRECTIONS
dditional Ongoing Studies
Several studies addressing critical issues that will
ffect the treatment recommendations in Table 3 have
een published in abstract form, were recently com-
leted, or are currently accruing patients. Rheingold
t al. [85] described a feasibility trial of an intensive
ultiagent chemotherapy reinduction/reintensiﬁca-
ion regimen for pediatric patients with ALL who
elapse on therapy. Fifty-three patients were treated
rom 1992 to 2002; 14 patients proceeded to alloge-
eic BMT in CR2. Jacobsohn et al. [86] reported the
esults of 15 infants (15 months) with high-risk ALL
reated with a cord blood or related donor allogeneic
CT in CR1 since 1992. Locatelli et al. [87] reviewed
he outcomes of 175 pediatric patients with ALL
reated with a related or URD SCT in CR2 at any of
1 AIEOP centers from 1998 to 2002. Gharib et al.
88] conducted a trial of alemtuzumab  Cy  TBI as
he conditioning regimen for matched or mismatched
RD SCT with T cell–replete grafts in 35 pediatric
atients with relapsed ALL. Watanabe et al. [89] re-
orted the results of the Children’s Cancer and Leu-
emia Study Group of Japan ALL 941 protocol, in
hich 463 pediatric patients with ALL were treated
rom 1994 to 1999 with one of 4 treatment protocols,
ncluding 44 children who received an autologous
BSCT in CR1. Eapen et al. [90] compared the re-
ults of URD BMT/cord blood transplantation with
hose of related donor BMT in 135 infants (18
onths) with ALL or AML reported to the Interna-
ional Bone Marrow Transplant Registry from 1990
o 2001. Lang et al. [91] compared the results of
D34-selected and/or CD133-selected haploiden-ical related allogeneic SCT (n  30) with those of
855
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8nmanipulated matched related allogeneic SCT (n 
8) in pediatric patients with ALL treated between
995 and 2003.
Other studies that are still accruing patients in-
lude the following: (1) a Children’s Oncology Group
hase II multicenter trial of the effectiveness of com-
ination chemotherapy with or without related donor
llogeneic PBSCT in pediatric (21 years) patients
ith very-high-risk ALL that includes a dose-escala-
ion study of imatinib mesylate in patients with Ph
LL; (2) a Fred Hutchinson Cancer Research Center/
ational Cancer Institute phase II multicenter trial of
onmyeloablative related or unrelated allogeneic
BSCT in pediatric and adult (70 years) patients
ith Ph ALL or chronic myeloid leukemia that has
reviously responded to imatinib mesylate; (3) a Fred
utchinson Cancer Research Center/National Can-
er Institute phase I/II trial of biologic therapy with
D8 Wilms tumor (WT1) gene-speciﬁc cytotoxic
-lymphocyte clones and interleukin 2 in pediatric
nd adult (75 years) patients with HLA-A2–positive
r HLA-A24–positive AML or ALL at high risk of
elapse after allogeneic SCT; and (4) an International
oordination Unit phase III multicenter trial of in-
uction therapy followed by consolidation and rein-
uction with or without late intensiﬁcation followed
y a maintenance regimen of allogeneic BMT in in-
ants (1 year) with ALL.
reas of Needed Research
After reviewing the evidence and highlighting the
tudies that are in progress, the panel recommends the
ollowing as the most important areas of needed re-
earch: (1) high-quality randomized controlled trials
nd other level 1 evidence to answer the questions
ddressed in this review; (2) studies to identify patients
ho are at very high risk for relapse (in addition to
h patients) and for whom more effective treatment
pproaches are needed; (3) unrelated marrow or blood
onor versus unrelated cord blood donor allogeneic
CT; (4) alternative nonfamily allogeneic donor ver-
us autologous SCT; and (5) studies that address the
ssue of adolescent and young adult patients to deter-
ine the appropriate age cutoff for pediatric versus
dult ALL.
ISCUSSION
The authors recommend methodology standard-
zation, including study design, end-point deﬁnitions,
nd reporting of study results. Multicenter random-
zed phase III comparative trials with large enroll-
ents and high statistical power are required to
dvance the ﬁeld more constructively than single-
nstitution phase II trials with one treatment arm or
etrospective multicenter or registry studies. In addi- r
56ion, publication of preliminary analyses should be
eserved for studies in which the trial was terminated
arly because of excessive toxicity or signiﬁcantly in-
erior or superior results. For most studies, a mini-
um of 3 years of follow-up in surviving patients is
eeded to detect signiﬁcant differences between treat-
ent arms. The authors advocate prompt reporting of
ature data in full-length article format. Abstracts do
ot adequately convey the full details of the study
esign or patient characteristics to meet evidence-
ased criteria for inclusion in systematic reviews or for
aking a true assessment of the widespread applica-
ility or effect of the treatment outside the scope of
he trial.
Many of today’s therapies for cancer result from
he randomized clinical trial process. It is currently
stimated that 60% of pediatric cancer patients par-
icipate in cancer clinical trials [92]. The authors ac-
nowledge the importance of removing barriers to
articipation in clinical trials, which may include pa-
ients’ reluctance to be randomized, lack of patient
ccess to clinical trials (due to geographic, transpor-
ation, cultural, and other barriers), ﬁnancial con-
traints (no or incomplete insurance coverage for trial
xpenses), stringent trial eligibility criteria, and reluc-
ance of community physicians to refer patients for
linical trial participation.
IMITATIONS OF THIS EVIDENCE-BASED LITERATURE
EVIEW
There are limitations to any evidence-based re-
iew of the published literature. The criteria for this
eview included reliance on published data—speciﬁ-
ally, peer-reviewed articles published since 1980.
npublished data, which were not included in this
eview, often represent negative ﬁndings and do not
ndergo peer review. We also excluded data published
n abstract form because the data are usually not peer
eviewed, are presented in an abbreviated format, and
ost often represent preliminary (not ﬁnal) data anal-
ses.
Limitations speciﬁc to this review topic include
he variability in reporting patient characteristics be-
ore SCT, the changing treatment modalities over
ime, and the paucity of randomized controlled trial
ata. The success of SCT is affected by prior sites of
elapse, presence of extramedullary disease, and dura-
ion of ﬁrst CR; many published studies did not report
his information, thus making it difﬁcult to compare
CT outcomes across studies. Chemotherapy regi-
ens, particularly those used for salvage, and pre-
CT conditioning regimens and post-SCT supportive
are have changed over the 20 years of trials in-
luded in this review. The effectiveness of salvage
egimens affects attainment of second or greater CR,
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Bhich in turn inﬂuences the effectiveness of SCT.
inally, randomized controlled trial data were lacking
n many areas of this review, which led to several
reatment recommendations based on small prospec-
ive studies or large retrospective registry reports.
UTURE INITIATIVES
This comprehensive systematic review of the
vailable evidence for the role of cytotoxic therapy
ith hematopoietic SCT in the therapy of pediatric
LL is the third in a series of sequential articles
ponsored by the American Society for Blood and
arrow Transplantation. Each review will summarize
he evidence regarding the role of cytotoxic therapy
ith SCT in the treatment of a speciﬁc disease byRCTs Ra
B&MText review in the series will address the role of SCT
n the therapy of adult ALL and will be published in
iology of Blood and Marrow Transplantation.
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ppendix A. Glossary of Terms
AIEOP Associazione Italiana di Ematologia ed Oncologia Pediatrica
ALL Acute lymphoblastic leukemia
ALL-REZ (Rezidiven) Relapsed ALL
AML Acute myeloid leukemia
Ara-c Cytarabine; cytosine arabinoside
ATG Anti-thymocyte globulin
BFM Berlin-Frankfurt-Munster
BM Bone marrow
BMT Bone marrow transplantation
Bu Busulfan
c-ALL Common acute lymphoblastic leukemia
CCG Children’s Cancer Group
CCR Continuous complete remission
CI Confidence interval
CNS Central nervous system
CR Complete remission
CR1 First complete remission
CR > 1 First or greater complete remission
CR2 Second complete remission
CR > 2 Second or greater complete remission
CR3 Third complete remission
CR > 3 Third or greater complete remission
CR4 Fourth complete remission
CSA Cyclosporine
Cy Cyclophosphamide
DFS Disease-free survival
EBMT European Group of Blood and Marrow Transplant
EFS Event-free survival
GITMO Gruppo Italiano Trapianto di Midollo Osseo
GVHD Graft versus host disease
HLA Human leukocyte antigen
IBMTR The International Bone Marrow Transplant Registry
IE Isolated extramedullary
IMUST International Marrow Unrelated Search and Transplant
KPS Karnofsky Performance Scale
LFS Leukemia-free survival
mAb(s) Monoclonal antibody(ies)
MRC Medical Research Council
MTX Methotrexate
OKT3 Orthoclone® anti-CD3 antibody
OS Overall survival
PBSCT Peripheral blood stem cell transplantation
Ph Philadelphia chromosome positive
POG Pediatric Oncology Groupndomized controlled trials
857
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8RR Relative risk
SCT Stem cell transplantation
SFGM Société Française de Greffe de Moelle
TBI Total body irradiation
TRM Treatment-related mortality
UKALL United Kingdom Acute Lymphoblastic Leukemia
URD Unrelated donor
VM-26 Teniposide
VP Etoposide
WBC White blood cell count
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